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Abstract 
Purpose: This study aims to determine prognostic factors for overall survival (OS) in 
prostate cancer patients after biochemical failure (BF), and identify a risk stratification 
system to predict OS for prostate cancer patients with BF. 
Methods: Univariable and multivariable Cox proportional hazards regression analyses, 
and recursive partitioning analysis (RPA) were conducted using data from 1246 patients 
who experienced BF in the Genitourinary Radiation Oncologists of Canada (GUROC) 
Prostate Cancer Risk Stratification (ProCaRS) database. Two thirds of patients were 
randomized into a Training cohort (n=831), and the final third into a Validating cohort 
(n=415). 
Results: Age, baseline PSA, T stage, Gleason score, hormone therapy, radiation therapy, 
nadir PSA, time to biochemical failure (TTBF) and pre-BF PSADT were significant 
(p<0.05) factors on univariable and multivariable analyses for OS after BF. RPA 
identified 6 unique patient groups that could be categorized into a 2-class risk group 
based on TTBF, pre-BF PSADT, Gleason score, and age. Comparing high risk to low risk 
groups, hazard ratios in the Training and Validating cohorts were 3.87 (95% CI: 2.64-
5.68; p<0.01) and 2.05 (95% CI: 1.22-3.45; p<0.01), respectively. 
Conclusions: The 2-class post-treatment risk stratification system allows for the 
identification of high risk and low risk patients in terms of OS after BF to help guide 
patient selection for future clinical trials and clinical treatment decision-making. 
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Chapter 1 : Introduction 
1.1 Prostate Cancer 
Prostate cancer is the third leading cause of death from cancer in men in Canada. It is also 
a significant burden affecting approximately 24,000 persons in 2015 alone. This 
represents 24% of all new cancer cases among Canadian men in 2015 (“Prostate Cancer 
Statistics - Canadian Cancer Society” 2015). There has been a reported increase in the 
incidence of prostate cancer since 1980. Currently there are 99 new cases of prostate 
cancer for every 100,000 Canadian men estimated in 2015. The rise from the 1980s was 
due to the increased use of prostate specific antigen (PSA) testing for screening, 
identifying both new cases and cases of slow growing cancer that were previously 
undiagnosed (Klotz 2012). Prostate cancer incidence in Canada had a sharp rise since its 
introduction in 1988 and peaked twice: once in 1993 (with PSA introduction), then in 
2001. The second peak in prostate cancer incidence in 2001 may be due to the increase in 
public awareness of prostate cancer since the disclosure of the federal health minister’s 
diagnosis in that year (Kachuri et al. 2013). 
The Canadian Cancer Society estimated that 4,100 men will die from prostate cancer in 
Canada in 2015 (thus 17 deaths for every 100,000 Canadian men). This indicates that 
prostate cancer deaths comprise 10% of all cancer deaths in men for the year 2015 
(“Prostate Cancer Statistics - Canadian Cancer Society” 2015). According to a report by 
the Public Health Agency of Canada, the cause-specific mortality rate for prostate cancer 
has declined since 1995. The report also outlines that the widespread use of screening 
methods have helped in the decreasing mortality and increasing survival trends in 
Canada. This may also be due to increased patient awareness of prostate cancer leading to 
earlier diagnosis, when disease is at an early stage at the beginning of treatment. 
Improvement in survival trends may also be due to the availability of different 
combination therapies for prostate cancer during the PSA era (Kupelian et al. 2003). A 
similar trend was found in the United States by the Surveillance, Epidemiology, and End 
Results (SEER) Program (Hankey et al. 1999). In the majority of prostate cancer cases, 
tumours are slow growing and can be treated successfully (Gomella et al. 2011). The 
2 
 
 
 
Canadian Cancer Society calculates that the 5 year survival rate for prostate cancer is 
approximately 96%. 
Risk Factors 
Risk factors for the development of prostate cancer that have been established in the 
medical literature include increasing age, race, and family history of prostate cancer. 
There are numerous risk factors that have been examined in the etiology of the disease 
such as obesity, or smoking; however studies pertaining to these factors are still 
inconclusive. The majority of prostate cancer cases are diagnosed in men greater than 65 
years of age and are relatively rare among men less than 50 years of age (Crawford 2003; 
McDavid et al. 2004). The incidence of prostate cancer varies between different ethnic 
groups and countries. The lower rates are among those in Asia, and the highest rates are 
among those in North America, Europe and certain parts of Africa. It has been suggested 
that these differences are a result of genetic susceptibility, unknown risk factors, or an 
artifact from differences in health care and differences in methods utilized in cancer 
registration (Grönberg 2003). Men who have immediate family members with prostate 
cancer have been reported to be 2.4 times likely to be also diagnosed with prostate cancer 
compared to those with relatives that do not have prostate cancer (Neal et al. 2000). 
Several case-control studies have investigated whether there was an association between 
high dietary fat intake and prostate cancer. Some studies suggest a significant relationship 
between this exposure and outcomes such as death or advanced stage of prostate cancer 
(Fradet et al. 2009). Smoking had not been found to be a risk factor for prostate cancer. 
However in several cohort studies, smoking at the time of diagnosis increased the risk of 
prostate cancer-specific death (Gong et al. 2007).  
Screening and Diagnosis 
Cells in the prostate that have lost normal control of their growth and division lead to 
prostate cancer. These uncontrolled cells have varying rates of growth and also have the 
ability to move to other parts of the body. Initial screening tools commonly used for 
prostate cancer detection include the Digital Rectal Exam (DRE) and the Prostate 
Specific Antigen (PSA) test.  
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PSA is a serum marker used in the screening of prostate cancer. It is a protein produced 
by the prostate gland and is mainly secreted into seminal fluid, but may also be found in 
the blood, especially among those with prostatic disease (Stenman et al. 1999). PSA is 
organ specific, but not tumour specific in the prostate (Abdel-Wahab and Silva 2008). 
While PSA tests have been used to screen for prostate cancer, there has been great 
concern about the ability for the test to distinguish between individuals with prostate 
cancer and patients with an enlarged prostate, otherwise known as benign prostatic 
hyperplasia (BPH) or other benign pathologies. Prostate cancer may still be present 
among men who are considered to have normal PSA levels (Nam et al. 2007). Cancers 
detected through screening tests may be relatively slow growing, and therefore are 
expected to have a good prognosis (Hankey et al. 1999). While screening can capture 
clinically significant cancers where mortality can be reduced with treatment, a major 
drawback is the over-diagnosis of prostate cancer among men with clinically insignificant 
cancers. In fact, a study conducted on over-diagnosis in PSA screening estimated that 
23%-42% of cancer cases detected through screening may not have been diagnosed had 
individuals not been screened (Draisma et al. 2009). These men undergo greater harm 
through diagnostic workup, treatment and their related side effects when their prostate 
cancer was not aggressive enough to have initially required treatment. Depending on the 
treatment administered, patients may experience urinary, bowel, sexual or other health 
issues. This not only affects patient quality of life, but also can produce extra costs to the 
healthcare system (Korfage et al. 2005; Corcoran et al. 2010). 
The benefits of population based prostate cancer screening remain questioned within the 
medical community. The two largest prospective randomized control trials on this topic 
have led to differing results (Wolf et al. 2010). A U.S. study from the Prostate, Lung, 
Colorectal, and Ovarian (PLCO) Cancer Screening Trial found that after 10 years of 
follow-up, there was no reduction in prostate cancer-specific mortality from PSA 
screening (Andriole et al. 2009). Similarly in an extended follow-up report at 13 years 
after the PLCO Cancer Screening Trial, there was no evidence of a reduction in prostate 
cancer mortality (Andriole et al. 2012). A European randomized control trial report 
demonstrated that there is a 20% reduction in prostate cancer mortality after 9 years of 
follow-up, and after a follow-up period of 11 years (Schröder et al. 2009; Schröder et al. 
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2012). Differences between the two studies that require consideration include dissimilar 
choices in PSA cutoff points, prescreening issues and compliance in screening arms 
(Wolf et al. 2010). 
An updated Cochrane review on prostate cancer screening included both these studies 
and three other randomized control trials in the literature. The investigators found that 
screening was associated with an increase in the number of men who were diagnosed 
with cancer. It was also reported that among the individuals in the screened group, the 
proportion of individuals with localized prostate cancer was greater, while the proportion 
of individuals with advanced prostate cancer was greater in the control group. Despite 
these findings, prostate cancer-specific mortality was not significantly reduced among 
those screened (Ilic et al. 2013). 
Refinements in PSA testing (PSA velocity, free total PSA, age and prostate volume 
corrected thresholds) and other biomarkers (such as PCA-3) as well as nomograms have 
been proposed to improve screening performance, but are currently unproven and are not 
part of standard care (Crawford et al. 2012). 
Beyond screening, PSA tests may also be used to monitor a patient who has already been 
diagnosed with prostate cancer, in other words through surveillance. It may also be used 
to detect the recurrence of prostate cancer, which may be experienced by approximately 
35% of men within 10 years of curative treatment (Pound et al. 1999; Bruce et al. 2012). 
The DRE is a physical test administered by a healthcare professional where the prostate 
gland is felt through the rectum. This test is to investigate the presence of an enlarged 
prostate gland or any other abnormality. While prostate tumours may be felt through the 
DRE, small localized tumours may be better detected through the combined use of both 
PSA and DRE. Even though the combination of PSA and DRE has a low sensitivity and 
specificity of trusted accuracy in detecting cancer, utilization of both tests allows for 
gathering more information and increasing the accuracy of early detection methods.  
Most prostate cancers are found through case finding at an individual level. In early 
stages of prostate cancer, there are generally no symptoms. If there are, they are quite 
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similar to the symptoms of BPH. Some potential symptoms at presentation include 
dysuria, polyuria, or having a feeling that the bladder has not completely emptied. Other 
symptoms associated with later stages of prostate cancer include bone pain, weight loss 
or pain in the pelvic area. Other men may seek out PSA testing because of a family 
history or other concerns about their individual risk of prostate cancer. Whether prostate 
cancer is suspected from PSA or the occurrence of symptoms, diagnosis can only be 
made with a biopsy (Mason and Moffat 2010).  
A transrectal ultrasound (TRUS) allows for an image of the prostate to be displayed. A 
TRUS probe, inserted into the rectum, uses ultrasonic waves to give an image of 
increased nodularity. Most commonly the cancer cannot be directly visualized and the 
ultrasound is used to guide needles to systematically sample regions of the gland to take 
biopsy samples. Biopsies are administered when an abnormal mass is found during a 
DRE or when a patient has a high PSA level (Gomella et al. 2011). Prostate biopsies of 8-
12 tissue samples are taken to determine whether abnormal findings are due to cancer or 
due to other benign causes. These samples are examined by a pathologist to confirm the 
diagnosis of cancer and to assign a tumour grade. Grading is assigned based on the 
similarity or differences between normal and cancer cells at a microscopic level.  
Grading and Staging 
The Gleason grading system for prostate cancer measures cancer aggressiveness 
(Thompson et al. 2007). A higher Gleason grade indicates that the aggressive cancer is 
more likely to spread. The Gleason score is calculated by the sum of the primary and 
secondary pattern, each given a score between 1 and 5, then added to give a final score 
between 2 and 10. The primary grade is for the most common tumour pattern while the 
secondary grade is for the second most common tumour pattern. This grading system has 
been noted to be directly correlated with mortality rates, to be a predictor of time to 
recurrence after surgery, and of response to therapy (King 2000).  
Small tumours confined within the prostate gland may be treated more successfully when 
compared to larger tumours within the prostate gland, or tumours that have spread 
beyond the prostate gland (Thompson et al. 2007). Thus it is important to be able to 
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classify and measure the extent and severity of prostate cancer for treatment planning and 
for assessing prognosis. Cancer cell metastases normally begin with local invasion, where 
prostate cancer cells invade nearby tissue. These cells are able to move outside the 
capsule of the prostate, resulting in progression of the cancer. Metastasis occurs when 
cancer cells have spread and have grown in a secondary location, damaging normal cells 
in these new areas. Lymph node and bone metastases are common sites of spread in 
prostate cancer (Mason and Moffat 2010).    
The classification most commonly used to describe the size and spread of a tumour is the 
tumour, node and metastasis (TNM) staging system which was first introduced in 1992 
by the American Joint Committee on Cancer (AJCC) and the International Union Against 
Cancer (UICC) (Cheng et al. 2012). Table 1 shows the latest TNM revision made in 
2010. It should also be noted that along with TNM staging, PSA level and Gleason score 
can be used to further classify tumours into four stages as shown in Table 2. 
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Table 1: 2010 AJCC Prostate Cancer Staging 
Primary Tumour (T)  
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Clinically inapparent tumour neither palpable nor visible 
by imaging 
T1a Tumour incidental histologic finding in 5% or less of tissue 
resected 
T1b Tumour incidental histologic finding in more than 5% of 
tissue resected 
T1c Tumour identified by needle biopsy (for example, 
because of elevated PSA) 
T2 Tumour confined within prostate 
T2a Tumour involves one-half of one lobe or less 
T2b Tumour involves more than one-half of one lobe but not 
both lobes 
T2c Tumour involves both lobes 
T3 Tumour extends through the prostate capsule 
T3a Extracapsular extension (unilateral or bilateral) 
T3b Tumour invades seminal vesicle(s) 
T4 Tumour is fixed or invades adjacent structures other than 
seminal vesicles, such as external sphincter, rectum, 
bladder, levator muscles, and/or pelvic wall 
Regional Lymph Nodes (N)  
NX Regional lymph nodes were not assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in regional lymph node(s) 
Distant Metastasis (M)  
M0 No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) with or without bone disease 
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Table 2: 2010 AJCC Anatomic Stage/ Prognostic Groups 
Group T N M PSA(ng/mL) 
Gleason 
Score 
I 
T1a-c N0 M0 <10 ≤6 
T2a N0 M0 <10 ≤6 
T1-2a N0 M0 Unknown Unknown 
IIA 
T1a-c N0 M0 <20 7 
T1a-c N0 M0 ≥10 and <20 ≤6 
T2a N0 M0 ≥10 and <20 ≤6 
T2a N0 M0 <20 7 
T2b N0 M0 <20 ≤7 
T2b N0 M0 Unknown Unknown 
IIB 
T2c N0 M0 Any Any 
T1-2 N0 M0 ≥20 Any 
T1-2 N0 M0 Any ≥8 
III T3a-b N0 M0 Any Any 
IV 
T4 N0 M0 Any Any 
Any N1 M0 Any Any 
Any Any M1 Any Any 
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Risk Stratification  
Patients are often classified into prognostic groups according to different factors known 
to affect prostate cancer outcomes. It is important for patient counseling and treatment 
decision-making (Mohler et al. 2010). Pretreatment risk stratification also plays an 
important role in the selection and stratification of patients for clinical trials and 
retrospective clinical research. There are a number of methods to present classification 
models including nomograms, look-up tables, and regression tree analyses. A simple and 
generalizable risk-group stratification model that has been widely used and accepted is by 
D’Amico et al 1998. This system uses three clinical factors and stratifies patients into 
three groups based on their risk of biochemical failure after radical prostatectomy or 
radiotherapy (D’Amico et al. 1998). Due to PSA screening, most men are diagnosed with 
non-palpable and clinically localized disease, when they would have been diagnosed 10 
years later by DRE. Since the proportion of patients with localized tumours has greatly 
increased, the risk of disease progression after radical prostatectomy has decreased 
greatly. Thus there is concern for older prognostic models, such as that of D’Amico, and 
their need to be reevaluated and updated to take into consideration the trends in stage 
migration (Hernandez et al. 2007; Han et al. 2001).  
In general, risk groups often include TNM stage, Gleason score, and PSA levels. From 
these variables, patients may be grouped into low risk, intermediate risk and high risk 
categories. Some organizations may use clinical variables to identify additional risk 
groups such as very-low risk, low-intermediate risk, high-intermediate risk, and very high 
risk. A number of risk stratification systems for patients exist from different institutions 
or organizations including the Genitourinary Radiation Oncologists of Canada (GUROC) 
and the National Comprehensive Cancer Network (NCCN) (Rodrigues et al. 2014; 
Mohler et al. 2010).  
Prostate Cancer Treatments 
A number of factors are considered in treatment selection for prostate cancer patients. 
Overall health status and life expectancy should be taken into account as well as type of 
prostate cancer, PSA level, stage and grade of cancer, metastasis and patient preference. 
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Potential life expectancy is also an important factor in the treatment decision for a 
patient. That is, if a patient is expected to have a long life expectancy, prostate cancer 
may be a cause of morbidity and mortality, and would therefore benefit from undergoing 
treatment. For a patient with a shorter life expectancy, the likelihood that a patient will 
die of prostate cancer is reduced due to competing hazards (Thompson et al. 2007; 
“Treatment of Prostate Cancer - Canadian Cancer Society” 2015). Actuarial tables and 
risk calculators are available to provide estimates of life expectancy based on patient age 
and comorbidities (NCCN, MSKCC) (“Prostate Cancer” 2015; Mohler et al. 2010). 
Patients with what is considered low-risk prostate cancer may be managed by active 
surveillance, although some still may opt for treatment. Patients with intermediate and 
high-risk or aggressive localized disease have a number of different treatment options 
including radical prostatectomy or radiotherapy (Locke et al. 2015). These three 
treatments are the primary management options for initial therapy for patients with 
clinically localized disease, although other modalities of treatment including high 
intensity ultrasound and cryotherapy have also been investigated (Mohler et al. 2010). 
Watchful Waiting 
Watchful waiting is sometimes known as deferred treatment or symptom-guided 
treatment. It encompasses the active decision in the delaying of therapy until the tumour 
progresses clinically either with or without symptoms. Upon the decision to start 
treatment, various options include hormone therapy, surgery or radiotherapy. The 
development of systemic symptoms usually is associated with metastatic disease. Thus, 
these patients will normally undergo palliative therapy to aid patient quality of life until 
the end of life. Watchful waiting thus results in the potential under-treatment of those 
with more aggressive disease and some men with potentially curable cancer may have 
their life harmed due to prostate cancer related mortality (Adolfsson 2008; Klotz 2006). 
Deferred treatment is a potential option for older patients with less aggressive tumours, 
for those with limited life-expectancy, and also for those who experience recurrence after 
curative therapies (Aus et al. 2005). The rationale behind watchful waiting is similar to 
that of active surveillance where prostate cancer is generally slow to progress, and reduce 
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overtreatment, especially among older men with competing risks of non-cancer mortality 
(Adolfsson 2008). 
Active Surveillance 
Active surveillance involves postponing immediate treatment, but requires PSA tests at 
regular intervals to monitor potential disease progression. The exact schedule for active 
surveillance differs between centers, but generally includes periodic TRUS guided 
prostate biopsy. Curative treatment is initiated at predefined points that indicate 
progression (Adolfsson 2008). This option of surveillance may be suitable for patients for 
varying reasons. Firstly, a patient’s cancer may not progress quickly to cause morbidity 
or mortality. Active surveillance would therefore reduce the risk of overtreatment (Klotz 
et al. 2010). Studies on active surveillance alone have varying guidelines in the selection 
of patients where some belong to low-risk groups and others also include patients with 
intermediate risk (Dall’Era et al. 2008). There is some concern that surveillance may 
minimize the time frame that would be optimal for curative treatment, but among 
carefully selected patients that may be at very low risk, active surveillance still provides a 
safe alternative to immediate treatment (Tosoian et al. 2011). It still allows the option for 
curative therapy when a patient is reclassified to be at higher risk. Should a patient decide 
to initiate other forms of treatment, there are side effects to be considered which may 
affect the patient’s quality of life. Currently, the data on the health related quality of life 
(HRQOL) of patients who undergo active surveillance compared to curative therapy offer 
different conclusions. Some studies indicate that men undergoing active surveillance 
have similar HRQOL to those undergoing active treatments, while other studies indicate 
that men under active surveillance have worse HRQOL (Daubenmier et al. 2006). 
The incorporation of evaluating repeat biopsies or even higher Gleason scores has been 
suggested for offering curative treatment (Morash et al. 2014). Proposed criteria for men 
on active surveillance include short PSADT or increased cancer volume or grade 
progression on repeat biopsy, or patient preference. There is no specified PSADT period 
for use, as it may be less effective in predicting prostate cancer death at the individual 
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level (Adolfsson 2008). Due to the differences in guidelines, study estimates on treatment 
outcomes are difficult to compare.  
Radiotherapy (RT)  
Radiotherapy is a treatment option for men whose disease seems potentially curable. This 
form of treatment utilizes high-energy X-rays to kill cancer cells. The basis of 
radiotherapy stems from the lack of ability for cancer cells to repair damage created by 
X-rays. Normal cells on the other hand when damaged have better ability for cellular 
repair. It is the differential between the antitumour effect and normal tissue effects of 
radiotherapy that leads to the potential of cure with acceptable side effects. Radiotherapy 
includes external beam radiation therapy (EBRT) or brachytherapy (BT) or a 
combination of both. Treating with these two methods often leads to high cure rates 
(Bruce et al. 2012). Even though most prostate cancers are at an early stage when 
diagnosed, some studies encourage early treatment for patients with longer life 
expectancy, especially since the natural course of disease leads to progression and 
metastasis (Johansson et al. 2004). 
EBRT 
In EBRT, X-rays are directed from a machine, known as a linear accelerator, onto the 
pelvis to target the prostate gland. As a common form of radiotherapy, EBRT offers the 
advantage of being able to be given to patients as an outpatient treatment. Most patients 
are able to tolerate the treatment without major side effects. This treatment is customized 
for each patient to ensure that the radiation is given in its highest dose to the prostate 
gland, and lowest dose to the surrounding tissues such as the bladder and rectum. CTs or 
MRI scans provide information on the prostate and surrounding tissues that are required 
in the planning stage for EBRT. While the treatment takes a few minutes, the 
administration of the treatment takes longer and must be repeated on a daily basis (Mason 
and Moffat 2010). Schedules vary from as short as one week to as long as 8 weeks. 
Common schedules are between 7 and 8 weeks of treatment. 
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In the early 1990s when 2 dimensional planning was utilized, total doses were limited 
from 66 to 70 Gy because of limited ability to deliver treatment precisely (Mohler et al. 
2010). Given new radiotherapy technology from new planning software and the use of 
CTs, known as 3D-conformal radiation therapy (3D-CRT), treatment can be better 
customized to the position and shape of a patient’s prostate gland. Not only does 
conformal radiotherapy allow dose escalating radiation reducing side effects, but it also 
provides a means of better tumour control (Locke et al. 2015; Kuban et al. 2008). 
Intensity-modulated radiotherapy (IMRT) is another development of conformal 
radiotherapy, offering the ability to target a concave treatment area to spare the rectum 
and also allowing good tumour control among patients with localized disease (Zelefsky et 
al. 2006).  Image-guided radiotherapy (IGRT) is also available in which radiation 
machines have image scanners to allow for minor adjustments and correction in the 
position of radiation beams. Such precision guided therapies have stimulated interest in 
shorter, high dose per fraction radiotherapy schedules between 1 to 4 weeks of treatment. 
Acute side effects and long-term side effects may exist with radiotherapy. Acute side 
effects such as inflammation of the urethra, bladder and rectum will cause discomfort 
from passing urine as well as diarrhea. These acute side effects may arise after 2 weeks of 
treatment and continue to worsen during the course of the treatment. The side effects may 
still be managed through various methods such as diet and medication. Long term side 
effects are uncommon, but has been reported to affect 1%-5% of radiotherapy patients 
(Mason and Moffat 2010).  
Brachytherapy 
BT is an important treatment option primarily for low and intermediate risk patients. 
There is also an evolving role of BT in high risk disease. BT involves the delivery of 
radiation internally using radioactive seeds. Sometimes radioactive seeds may be 
implanted permanently, as the seeds gradually lose their radioactivity over time. This 
method would be less likely to affect the rectum and nerves near the prostate since the 
seeds emit low-energy, short range radiation. Treatment with BT alone is a common 
option among patients with early, localized prostate cancer (Mohler et al. 2010). This 
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method of radiotherapy may be unable to irradiate cancer cells that have extended beyond 
the prostate capsule (Mason and Moffat 2010) . 
Low dose rate BT (LDR-BT) can be conveniently administered in one day as a one-time 
procedure with the help of TRUS to guide the placement of irradiated seeds (Morton and 
Hoskin 2013). This treatment method reportedly has excellent outcomes and low 
morbidity among patients with low risk prostate cancer. When compared to RP or EBRT, 
LDR-BT performs well with long-term survival and lower toxicity. LDR-BT is also 
associated with lower complication rates. LDR-BT may be used as a monotherapy or 
along with EBRT as a boost for early detected prostate cancer (Skowronek 2013).  
An alternative is the use of temporary high dose rate BT (HDR-BT) where implanted 
catheters are used to introduce a radioactive iridium source into the prostate gland. This 
may require multiple treatments. An advantage however is that it allows more control 
over dose escalation that is not available with LDR-BT (Skowronek 2013).  
Both HDR-BT and LDR-BT may be used with or without EBRT and hormone therapy. 
HDR-BT with EBRT is a common method of therapy for patients with intermediate and 
high-risk prostate cancer. HDR-BT has been recommended to be used in combination 
with EBRT since EBRT requires a dose escalation above 70-76 Gy to optimize cancer 
control and also because HDR-BT is able to spare adjacent tissues from risk of exposure. 
Several randomized controlled trials of HDR-BT also observed a 10-15% decrease in the 
risk of biochemical failure, but also increased rectal toxicity. Outcomes on other 
clinically meaningful endpoints are uncertain (Morton 2014; Michalski et al. 2013). In 
general, combining BT in treatment for dose escalation has less toxicity compared to 
increasing EBRT doses alone (Morton and Hoskin 2013). 
Surgery 
RP is a surgical treatment offered to patients with localized disease to control cancer. RP 
encompasses the removal of the prostate gland, seminal vesicles and part of the urethra. 
Depending on the extra characteristics of the tumour and patient sexual function, RP may 
or may not be nerve-sparing. RP is a method of treatment that potentially removes all 
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cancer cells and may be recommended when the cancer has not spread outside the 
prostate (patients with T1 or T2 tumours). Surgical removal of the prostate may be used 
in combination with other treatments such as radiotherapy (Thompson et al. 2007). 
Since the prostate is removed, it is expected that the recurrence of cancer is low among 
patients with localized disease. If the prostate gland is removed, a small amount of 
prostate tissue may remain and produce low levels of PSA.  It has been reported that 35% 
of men that are given this method of treatment will have a detectable level of prostate-
specific antigen in their serum within 10 years of the surgical treatment (McLeod 2005). 
Perioperative morbidity must be taken into consideration when considering RP. Because 
of this, RP has been primarily recommended for patients who have life expectancies 
greater than 10 years (Mohler et al. 2010).  
Hormone Therapy 
Prostate cancer cells require the hormone testosterone for their growth. If a tumour is 
deprived of testosterone, cancer cells can die from apoptosis. Hormone therapy, also 
known as androgen deprivation therapy (ADT), helps to control tumour growth, but is 
unable to completely eliminate it. ADT may be used in various stages of prostatic 
disease. It may be used by itself in the treatment of localized advance cancer or with 
metastatic disease, or with radiotherapy as an adjuvant treatment (Mason and Moffat 
2010). The use of neoadjuvant (prior to main treatment using RP or radiation therapy) or 
adjuvant (after RP or radiotherapy) hormone therapy differs from its use as a primary 
treatment (Thompson et al. 2007). 
Luteinizing hormone-releasing hormone (LHRH) agonists or bilateral orchiectomy are 
both effective for treating prostate cancer. If testosterone cannot be suppressed to levels 
less than 50 ng/mL with the medical or surgical castration, additional changes in hormone 
treatment using estrogens, anti-androgens, or steroids may be considered. Adverse events 
from the use of ADT include, but are not limited to, osteoporosis, insulin resistance, 
increased risk for cardiovascular disease and diabetes, and loss of secondary sex 
characteristics (Mohler et al. 2010). 
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1.2 Biochemical Failure 
Follow-up assessments after treatment for prostate cancer are important for identifying 
and treating any side effects, and also detecting recurrence of prostate cancer. These 
visits usually include PSA blood tests and DRE. Patients treated by EBRT should have 
slow declining or stable PSA levels following completion of treatment. However it is 
important to realize that there are instances when there is one or two sequential rises in 
PSA levels, followed by a fall without treatment to lower PSA levels, known as PSA 
bounce. This benign phenomenon has been reported to occur primarily after BT, but also 
after other treatments including EBRT and three-dimensional conformal radiation therapy 
(Sengoz et al. 2003; Crook et al. 2007). The implications of PSA bounces are uncertain. 
Some studies have reported improved survival among those who experience the bounce, 
while other studies did not find this association (Hinnen et al. 2012; Stock et al. 2003). In 
general, 30-40% of successfully treated men through BT experience a PSA bounce within 
12-18 months after treatment. However there are differences in frequency of PSA bounce 
reported in literature due to varying definitions of PSA bounce (Caloglu and Ciezki 
2009). Currently there is no definition that is able to differentiate between rising PSA 
levels caused by the recurrence of prostate cancer from a benign PSA bounce.  
In other instances of rising PSA levels, biochemical failure is suspected. Defining 
biochemical failure among patients treated with RP is simpler compared to patients 
treated with radiation therapy, since the main producer of PSA (the prostate) has been 
removed. After RP, PSA levels are expected to be undetectable within 6 weeks (Cookson 
et al. 2007). In a study comparing several definitions of biochemical failure after RP, a 
PSA value of 0.4 ng/mL followed by another increase was the strongest indicator of the 
development of distant metastasis (Stephenson et al. 2006).  
Prior to January 2005, a definition of biochemical failure after external beam 
radiotherapy (EBRT) as defined by the initial ASTRO consensus was “three consecutive 
rises of PSA levels after a PSA nadir” (Roach et al. 2006). The date of biochemical 
failure in this definition was determined as the date halfway between the nadir date and 
the first PSA rise or any rise in PSA level significant enough to commence therapy. A 
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Consensus Conference sponsored by the American Society for Therapeutic Radiology 
and Oncology (ASTRO) and the Radiation Therapy Oncology Group (RTOG), brought 
forward concerns of needing a revised definition for biochemical failure. The previous 
definition was not based on clinical progression or survival and biochemical failure did 
not necessarily mean patients were experiencing clinical failure (Nielsen 2007). It 
performed poorly for patients who underwent hormonal therapy, as a false failure could 
be triggered by small PSA rises after hormone withdrawal. Given the issues with the 
previous definition of biochemical failure, it was recommended that the ASTRO 
definition be revised to “a rise by 2ng/mL or more above the nadir PSA after EBRT with 
or without HT” (Roach et al. 2006). An example of meeting this definition is illustrated 
in Figure 1 and is now referred to as the Phoenix definition of biochemical failure. Even 
if a patient meets the definition of having experienced biochemical failure, there is no 
requirement for immediate treatment (McLeod 2005). 
Biochemical failure is experienced by approximately 35% of prostate cancer patients 
within 10 years of receiving treatment. Among patients who have undergone radical 
prostatectomy, the 10 year actuarial biochemical progression-free survival (PFS) was 
reported to be 68%. Patients who were given radiotherapy were found to have a 10 year 
actuarial biochemical PFS between 50-70%. Among the 35% of patients who have 
biochemical recurrence, a third developed evidence of metastatic disease within 8 years 
from when their PSA was elevated (Bruce et al. 2012).  
The clinical course of patients with biochemical failure is variable. Some patients quickly 
experience progression to metastasis, while other patients do not. A study comparing 
overall survival among men with and without biochemical failure over at 10 year period, 
found that overall survival was similar for patients after RP. In this study, biochemical 
failure was defined as a serum PSA of 0.2 ng/mL or greater. Among those with 
biochemical failure, the 10 year overall survival rate was 88%, among those without 
biochemical failure, the 10 year overall survival rate was 93% (Jhaveri et al. 1999, Pound 
et al. 1999).  
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Treatment options for patients with biochemical failure may include watchful waiting, 
salvage BT, salvage RP and ADT. Salvage RP may be an option in selected patients after 
EBRT or BT provided that there is no metastasis (Mohler et al. 2010). However, salvage 
RP is not usually recommended due to associated surgical risks including urinary and 
sexual dysfunction. BT after biochemical failure may be considered for treatment, but the 
optimal dose of radiation still requires study. The early use of ADT compared to the late 
use of ADT is still debated, but has been reported to be considered the standard of care 
(Bruce et al. 2012). Factors that influence the timing of initiating ADT include PSA 
doubling time (PSADT), patient anxiety and the expected side effects of hormone 
therapy. Biochemical failure with elevating PSA levels cause anxiety among patients and 
its management is varied and still debated. 
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Figure 1:  Example of PSA Follow-Up Profile Depicting Biochemical Failure 
PSA: Prostate Specific Antigen 
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1.3 Prostate Cancer Endpoints 
Within clinical trials, clinical endpoints refer to important patient–related outcomes being 
measured. Clinically meaningful endpoints refer to endpoints that directly measure how a 
patient feels or functions, or how long they survive. These endpoints can be either 
objective, for example, when looking into survival or a clinical event; or subjective, for 
example, using a score or rating for symptoms or health related quality of life (De 
Gruttola et al. 2001). 
Endpoints commonly studied for prostate cancer include Overall Survival (OS), Prostate 
Cancer-Specific Survival (PCSS), and Metastasis-Free Survival (MFS). OS considers 
deaths from any causes as events. PCSS is estimated by considering only deaths due to 
prostate cancer and often considers all other causes censored. MFS considers the period 
until metastasis is detected as an event. These endpoints often require long follow-up 
periods, therefore surrogate endpoints are often sought out as it not only reduces the 
duration of clinical trials, but also costs (Fleming and DeMets 1996).  
The National Institutes of Health (NIH) has defined surrogate endpoints as biomarkers 
intended to substitute for a clinical endpoint (Aronson 2005). Biomarkers can be 
objectively measured and assessed as an indicator of normal biologic processes. They are 
used because they are faster and easier to study. Because prostate cancer is generally 
slow growing, using a direct endpoint is often not practical when analyzing effects due to 
low event rates and long time-to-events post treatment. 
Surrogate endpoints can be laboratory measures or a physical sign in a patient that can be 
used as a substitute for a clinically meaningful endpoint. These markers may help in 
patient selection for clinical trials and management of disease (Armstrong and Febbo 
2009). Ideally, a surrogate endpoint should be within the pathway in which disease 
occurs, or one where intervention can alter the progression of disease to provide 
meaningful benefit. Sometimes biomarkers may just be correlated with disease and are 
not directly related to survival or how a patient feels. Therefore while all surrogate 
endpoints are biomarkers, not all biomarkers can be considered good surrogate endpoints 
(Aronson 2005).  
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The natural history of prostate cancer in men with biochemical failure varies greatly. 
While biochemical failure has a slight association with metastases, it is not a suitable 
surrogate endpoint for progression or prostate cancer specific mortality (Simmons et al. 
2007). The current definition of biochemical failure is poorly correlated with clinical 
outcomes such as overall survival, prostate cancer specific survival and metastasis free 
survival. Therefore better models using clinical outcomes based on other factors than 
biochemical failure alone are required. Considerations for other definitions of an 
appropriate surrogate endpoint for prostate cancer are required for clinical trials and for 
treatment selection after biochemical failure.  
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1.4 Recursive Partitioning Analysis 
Recursive partitioning analysis (RPA) is a type of prediction model that is utilized to 
create distinct prognostic groups. This method of building decision trees is useful as it 
divides patients into groups based on their survival, i.e. time at risk  (Park et al. 2009; Al-
Nachawati et al. 2010). RPA may also divide patient groups by the proportion of 
experiencing binary outcomes. RPA has been used in a number of different settings such 
as brain metastases and glioblastomas, to develop useful prognostic models (Scott et al. 
2012; Gaspar et al. 1997). Models developed were able to divide patients into subgroups 
that could be easily used for patient care and clinical trials. 
In RPA, the first variable that is found which best splits the data into two homogenous 
groups based on a specific threshold or cut-point, makes the primary node. For survival 
outcomes, the split corresponds to calculated hazard ratios. Within each subgroup, the 
next best split is applied to each group. The division into groups is guided by a principle 
known as “impurity reduction”, where daughter nodes of a tree share more similarities 
than parent nodes  (Strobl et al. 2009). The splits in the decision tree are known as 
“leaves”, where no other split is possible, as is depicted in Figure 2. Leaves are also 
known as terminal nodes (Gaspar et al. 1997). In the identification of prognostic factors, 
RPA makes fewer modeling assumptions than proportional hazards. If observations have 
missing values in a variable being evaluated, it is first ignored for calculating the 
impurity reduction. The same observations are later included in calculations for impurity 
reductions in other splits. This method thus does not result in heavy data loss as it would 
if missing values were completely ignored. 
Splitting of nodes in RPA continues until all leaf nodes are pure, or until a pre-specified 
number of observations in a node is reached, or a node cannot be split given a minimum 
threshold in measuring impurity (Strobl et al. 2009). A concern for over-fitting exists 
with prediction modelling. In RPA, a solution to this problem is to “prune” the decision 
trees. This process removes any splits in the tree that do not add to the prediction 
accuracy of the model. In practice, this typically translates into requiring a minimum 
number of 20 observations in a node to enable further splitting, and trimming of 
downstream branches determined to be of less importance or of insufficient sample size 
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for further analysis (Pavlopoulos et al. 2004). Additionally for clinical application 
purposes, RPA generated cut-points may be further modified and rounded to represent 
more clinically meaningful values. 
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Figure 2: Decision Tree from Recursive Partitioning Analysis 
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Chapter 2 : Literature Review 
The literature review was conducted through PubMed using the search strategy: 
((biochemical*[ti] OR PSA[ti] OR prostate specific antigen[ti]) AND (failure*[ti] OR 
recurren*[ti] OR relapse*[ti])) based on Nguyen et al. who identified 19 studies from 
1980 to 2013, which examined prognostic factors among patients with BF after RT or RP 
for MFS, PCSS and OS (Nguyen et al. 2015). An additional 3 studies were identified 
from 2013-2015, of which all 3 had RT as primary treatments prior to BF. Predictive 
variables are those significantly associated (α=0.05) with an outcome variable, and may 
subsequently be used to predict values for the outcomes. Variables that were found to be 
independently predictive were significantly associated in the presence of other variables. 
2.1 Prognostic Factors for MFS among patients with BF 
In a review of the literature on prognostic factors among men who experience 
biochemical failure after RP or RT, it was found that PSADT, Gleason score and time to 
biochemical failure (TTBF) were more consistently found to be prognostic of MFS. 
Representative studies are discussed below. 
PSADT has been analyzed using various cut points or as a continuous variable. A number 
of studies have found PSADT as predictive of MFS in both univariable and multivariable 
analyses. In a retrospective study analyzing 450 men treated with RP who never received 
adjuvant or salvage therapy before metastatic disease development, Antonarakis et al. 
examined PSADT as in the following categories <3.0, 3.0-8.9, 9.0-14.9 and ≥15.0 months 
and Gleason score as ≤ 7, 7 and 8-10 (Antonarakis et al. 2012). An earlier study 
conducted by the same group found Gleason score, T stage, TTBF, PSADT and age as 
predictive of MFS in univariable analysis, but upon multivariable analysis only PSADT 
(categorized as ≥9, 3-8.9 and <3 months) was independently predictive of MFS 
(Antonarakis et al. 2011). A study of PSA kinetics on MFS found that changes in PSADT 
and in log PSA slope were independent predictors in multivariable analysis (Antonarakis 
et al. 2012).  
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A study analyzing the natural history of BF after RP with adjuvant radiotherapy found 
that on multivariable analysis, increasing Gleason score and PSADT of less than 6 
months were significantly associated with systemic progression. The authors defined 
systemic progression as having a demonstrable metastasis on radionuclide bone scan or 
computerized tomography (CT) scan, or on biopsies outside the prostatic bed. PSADT 
was categorized at 6 month intervals. Advanced T stage was found to be associated with 
the risk of systemic progression, but was not statistically significant. TTBF was also a 
factor analyzed in this study. However it did not predict systemic progression or PCSS 
(Boorjian et al. 2012). This finding is very similar to that of Roberts et al; where 
multivariable analysis indicated PSADT as a significant factor for predicting systemic 
progression. Univariable analysis identified PSADT and Gleason score as independent 
predictors (Roberts et al. 2001). Although TTBF was not found to be an independent 
predictor for MFS and PCSS, it was identified as such in another study by Buyyounouski 
et al. This group also found that Gleason scores of 7 to 10, PSA nadir ≥ 2ng/mL, and 
decreasing radiation dose were independently predictive of MFS (Buyyounouski et al. 
2008). 
TTBF has been identified as an important factor after RT to identify patients at high risk 
for death and metastasis (Buyyounouski et al. 2008). Multivariable analysis conducted 
among 213 patients treated with LDR-BT also indicated PSADT and TTBF as significant 
predictors of MFS (Stock et al. 2008). These factors were also found to be significant in a 
different group of 264 patients undergoing BT±EBRT (Ko et al. 2014). 
These significant factors may be useful when discussing adjuvant therapies for patients 
who have experienced BF. A shorter TTBF has been thought to represent an increased 
likelihood of metastasis. TTBF greater than 3 years after RP may be likely an indication 
of local recurrence. As a strong predictor of metastasis, PSADT has been discussed to 
represent aggressiveness of the original tumour, while TTBF provides information on 
residual disease following RP (Roberts et al. 2001). 
Table 3 summarizes these results. 
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Table 3: Summary of Prognostic Factors for Metastatic Free Survival after Biochemical Failure 
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Where x indicates that a variable was investigated, U indicates a factor was significant upon univariable analysis, M indicates a factor 
was significant upon multivariable analysis 
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2.2 Prognostic Factors for PCSS among patients with BF 
PSADT, Gleason score and TTBF have been identified most consistently as predictors of 
PCSS in both univariable and multivariable analyses. Although age has been examined in 
many univariable and multivariable models, it has been reported to be significant in only 
one study (Boorjian et al. 2011). Similarly T stage has also been studied, however it has 
not been found to be statistically significant in a number of studies or does not add value 
as a pretreatment variable to predict PCSS in the use of risk groups (D’Amico et al. 
2003). Other factors that have occasionally been found to be prognostic of PCSS include 
PSA nadir, and pretreatment PSA values of >20ng/mL. Representative studies are 
discussed below and are summarized on Table 4. 
In a study of 211 men who experienced BF after RT, TTBF was found to be an 
independent predictor of PCSS (Buyyounouski et al. 2008). In a more recent study of 
1722 men with BF after RT by Buyyounouski et al, univariable analysis found Gleason 
score and TTBF were the most discriminatory prognostic factors for PCSS. Specifically 
TTBF <18 months was most able to identify patients at risk for death from prostate 
cancer. Initial PSA and radiotherapy dose were not found to be predictive of PCSS 
(Buyyounouski et al. 2012). These findings suggest TTBF and PSADT may be useful as 
surrogate endpoints for PCSS in men with BF. Others found a cut-point of TTBF <2 
years or PSADT <12 years was a predictor of death from prostate cancer within 6 months 
of experiencing BF among radiotherapy patients (Denham et al. 2008).  
Different from other studies, a research group analyzing predictors of PCSS among 160 
men with BF after EBRT found that Gleason Score and pretreatment PSA >20ng/mL 
were significant predictors upon multivariable analysis (D’Amico et al. 2003). T stage 
was analyzed within this cohort but was not statistically significant. In a multivariable 
analysis of 465 patients experiencing BF after EBRT, Gleason score were also found to 
be significant predictors of PCSS, as well as PSADT and earlier intervention (Kim-Sing 
et al. 2004). 
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Patient pretreatment (initial) PSA (iPSA) was found in one study to be a good predictor 
of biochemical recurrence-free survival after RP or RT, but not as a prognostic factor for 
PCSS after BF.  Gleason score and T Stage were found to be independently associated 
with PCSS, but age was not predictive. PSADT was found to be correlated with PCSS, 
while TTBF was found to be a prognostic factor (Denham et al. 2009) 
Prognostic factors among patients experiencing BF after RP vary slightly from patients 
experiencing BF after RT.  Early TTBF was found to be statistically associated with an 
increased risk of prostate cancer death in 3 studies using multivariable analysis of 379 RP 
patients, 264 and 175 RT patients (Freedland et al. 2006; Ko et al. 2014; Shilkrut et al. 
2013). A larger study of 2426 patients with BF after RP, TTBF was not associated with 
PCSS, nor with systemic progression. Instead patient age, Gleason score, T stage and 
PSADT were predictive of PCSS (Boorjian et al. 2011). 
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Table 4: Summary of Prognostic Factors for Prostate Cancer Specific Survival after Biochemical Failure 
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Boorjian et al 2011 2426 RP  PSA ≥0.4 ng/ml M M U M M x    x  x    
Buyyounouski et al 2008 211 RT Nadir + 0.2ng/ml 
U x 
U 
M 
U     x    x U  
Buyyounouski et al 2012 1722 RT  Nadir + 0.2ng/ml 
U x 
U 
M 
x         x x  
D’Amico et al 2003 160 RT 3 consecutive rises M x       M       
Denham et al 2008 436 RT Nadir + 0.2ng/ml x x M M x    x       
Denham et al 2009 454 RT Nadir + 0.2ng/ml U U M x x    M       
Freedland et al 2006 379 RP PSA ≥0.2 ng/ml 
x x 
U 
M 
x x  x  x       
Kim-Sing et al 2004 544 RT Vancouver Criteria U 
M 
U  
U 
M 
 
U 
M 
  U U      
Ko et al 2014 264 RT Nadir + 0.2ng/ml x x M x x    x x     x 
Shilkrut et al 2013 175 RT Nadir + 0.2ng/ml M x M  x    x x x     
Where x indicates that a variable was investigated, U indicates a factor was significant upon univariable analysis, M indicates a factor 
was significant upon multivariable analysis
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2.3 Prognostic Factors for OS among patients with BF 
A summary of prognostic factors by study for OS can be found in Table 5. TTBF and 
PSADT were commonly reported to be significant predictors of OS, where OS was 
defined as the interval of time from BF to death from any cause. Age was found to be 
predictive of OS in a few studies upon multivariable analysis. However, it was found to 
be a weak predictor of OS in one study of 436 men with BF after RT, and was not 
significant in a study of 154 RT patients with BF after examining for age, pretreatment 
PSA, TTBF, PSA nadir, Gleason score, T stage and rise in PSA (Denham et al. 2009).  In 
fact, none of the examined variables were found to be predictive of OS (Sandler et al. 
2000). 
In a univariable analysis of variables, Gleason score, T stage, TTBT, PSADT and age 
were predictive of OS, but after multivariable analysis, only PSADT when categorized as 
≥9, 3-8.9 and <3 months was found to be predictive of OS (Antonarakis et al. 2011). 
Another study by D’Amico et al., found that PSADT <6 months and age were associated 
with shorter OS in multivariable analysis (D’Amico et al. 2006). PSADT of <3 months 
was found to be of greatest risk of OS among patients, although the majority of patients 
in the cohort studied by Freedland et al.,  had intermediate PSADTs between 3 and 8.9 
months (Freedland et al. 2007). These studies indicate that in general, shorter PSADT are 
significantly associated with OS.  
Freedland et al., also found that earlier TTBF, age and Gleason scores ≥8 were associated 
with OS. TTBF cut points varied between studies that found it to be a significant factor. 
One study dichotomized TTBF at 18 months, while another at 2 years (Buyyounouski et 
al. 2008; Hachiya et al. 2006). Some factors that were significant in other studies include 
PSA velocity and pretreatment PSA (Wo et al. 2009; Denham et al. 2009). 
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Table 5: Summary of Prognostic Factors for Overall Survival after Biochemical Failure 
Author, Year n T
re
at
m
en
t 
B
F 
d
ef
in
it
io
n
 
G
le
as
o
n
 S
co
re
 
T 
st
ag
e 
TT
B
F 
P
SA
D
T 
ag
e
 
ra
ce
 
Su
rg
ic
al
 m
ar
gi
n
  
P
re
tr
ea
tm
en
t 
P
SA
 
P
SA
 n
ad
ir
 
Ti
m
e 
to
 n
ad
ir
 
C
o
m
o
rb
id
it
y 
sc
o
re
 
P
SA
 v
el
o
ci
ty
 
U
se
 o
f 
A
D
T 
af
te
r 
B
F 
B
ED
 
Antonarakis et al 
2011 
346 RP  PSA ≥0.2 ng/ml 
U U U 
U 
M 
U x x x       
Buyyounouski et 
al 2012 
1722 RT Nadir + 0.2ng/ml 
x x M M     M      
D’Amico et al 
2006 
81 RT  2 consecutive rises of at least 
0.2ng/mL after PSA level 
>1.0ng/mL 
x x  M M   x       
Freedland et al 
2007 
379 RP PSA ≥0.4 ng/ml 
M x M M M x  x       
Hachiya et al 
2006 
155 RP 2 consecutive rises ≥0.4ng/mL U 
M 
U 
 
     
U 
M 
      
Sandler et al 
2000 
154 RT 3 consecutive rises 
x x x  x   x x x     
Wo et al 2009 89 RT 2 consecutive rises ≥0.2ng/mL 
after nadir 
x x x  x      M M   
Ko et al 2014 264 RT Nadir + 0.2ng/ml x x M x x   x     x x 
Kim et al 2013 108 RT Nadir + 0.2ng/ml M x M  M   x   M M x  
Where x indicates that a variable was investigated, U indicates a factor was significant upon univariable analysis, M indicates a factor 
was significant upon multivariable analysis
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2.4 Objectives 
While a number of factors have been indicated in previous studies as prognostic for OS, 
PCSS and MFS, within the studies there were differences not only in variables examined, 
but also BF definitions and sample sizes. The studies found had sample sizes between 81 
and 2426 patients treated with either RP or RT. The patient population also varied in 
terms of their treatment for BF. Some patients included in studies had received adjuvant 
therapy, while others had not. There is much controversy surrounding the timing in 
administration of salvage therapy for patients experiencing BF, thus it is important to 
develop a model of clinical outcomes at the time of BF. 
Currently no risk stratification system has been made to identify patients at high risk or 
low risk of death after BF. The use of risk stratification systems would play an important 
role in patient selection in clinical trials and decision-making to determine the best 
treatments for patients of differing risks of having clinically significant endpoints after 
BF.  
There are two main objectives of the current study: 
1) To identify prognostic factors of overall survival after BF within the GUROC 
ProCaRS database 
2) To build a risk stratification system that would allow the identification of low 
and high risk groups of patients with BF 
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Chapter 3 : Method 
3.1 GUROC ProCaRS Database 
The Genitourinary Radiation Oncologists of Canada (GUROC) Prostate Cancer Risk 
Stratification (ProCaRS) database consists of 7974 patients. Patient data were compiled 
from 7 databases at 4 institutions including 3771 patients from the British Columbia 
Cancer Agency (BCCA), 1752 patients from Princess Margaret Hospital (PMH), 2257 
patients from L’Hotel Dieu de Québec and 194 from McGill University Health Centre 
(Rodrigues et al. 2014). For this study the GUROC ProCaRS database was used to 
determine predictors of overall survival after biochemical failure. These factors were also 
used to identify a low risk and high risk group among men experiencing biochemical 
failure.  The GUROC ProCaRS database was commissioned by GUROC and solely 
encompasses information on patients treated with radiotherapy.  
Ethics approval for the study was obtained from the University of Western Ontario 
Research Ethics Board for Health Sciences Research Involving Human Subjects 
(HSREB) and can be found in Appendix I. 
Of the 7974 patients in the database, 1246 (15.6%) were identified who met the Phoenix 
definition of biochemical failure (2.0ng/mL above nadir PSA). Patients who were given 
salvage hormone therapy prior to reaching biochemical failure were excluded from this 
analysis. These patients were excluded because the initiation of their treatment for 
biochemical failure was dependent on other clinical factors as opposed to a specific PSA 
value. Two thirds of the 1246 patients were randomly grouped into a training set (n=831), 
and the final third was grouped into a validation set (n=415) for both univariable and 
multivariable Cox proportional hazards regression analyses, and recursive partitioning 
analysis.  
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3.2 Statistical Analyses 
Descriptive analyses on patient clinical characteristics, treatment characteristics, and 
patient outcome and biochemical data were conducted. These statistics were reported as 
mean and standard deviations for continuous variables and as frequencies and 
percentages for categorical variables. Chi-square tests (or Fisher’s exact test as 
appropriate) for categorical data and two-sample t-tests for continuous data were 
conducted to assess for differences in characteristics between Training and Validating 
groups. Categorical variables included T stage, total Gleason score, positive cores greater 
or equal to 50%, bilateral biopsy status, radiation treatment type, year of initiation of 
radiotherapy, EBRT dose > 70Gy, hormone therapy, causes of death and biochemical 
failure ≤5 years from date of radiotherapy. Continuous variables include age, baseline 
PSA, EBRT dose and fractionation, LDR and HDR doses, duration of adjuvant hormone 
therapy, nadir PSA, TTBF, PSADT, time to nadir and time from BF to death. PSADT 
was also assessed as a categorical variable defined as 0-6 months, 6-12 months and 
greater than 12 months. 
Univariable Cox proportional hazards regression analyses were conducted to determine 
factors that were individually associated with overall survival among patients who 
experienced BF. Multivariable Cox proportional hazards regression analyses were 
conducted using backward elimination procedures, sequentially removing factors until all 
remaining covariates had p-values < 0.05, to identify significant predictors of overall 
survival after BF among patients in Training set. Final predictors identified from 
multivariable analyses and from the literature review were included in RPA using data in 
the Training dataset to identify a high risk and low risk group for overall survival after 
BF. Variables such as age, PSADT, TTBF were kept as continuous variables as the RPA 
would choose the values to stratify factors according to the impurity reduction principle. 
A minimum number of 20 observations in a node before further splitting was specified 
(Pavlopoulos et al. 2004). Downstream branches of less importance or of insufficient 
sample size were trimmed manually.  
From preliminary risk groups identified by RPA, overall survival was estimated from 
Kaplan-Meier survival curves. Log-Rank tests were utilized to determine if the risk 
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groups were statistically different from each other and between Training and Validating 
groups. Based on overall survival estimates from Kaplan-Meier survival plots, high risk 
and low risk groups were identified. Hazard ratios comparing high risk to low risk were 
reported with associated p-value and C-indices with 95% confidence intervals (CI). 
Log-minus-log survival plots were used to graphically assess for any violation of the 
proportional hazards assumption. Further diagnostic testing through Kolmogorov tests 
were also conducted. Any violation in the proportional hazards assumption identified 
using either method required that risk groups be assessed as a time-dependent covariate 
(Vittinghoff et al. 2012). Cox proportional hazards regression incorporating a time-
dependent covariate with risk group (i.e. riskgroup*log(survival)) was utilized to 
determine if risk group remained a significant predictor of overall survival over time. 
All descriptive, univariable and multivariable Cox proportional hazards regression 
analyses were conducted using SAS version 9.4 software (SAS institute, Cary NC). 
Recursive partitioning analysis was conducted using the R language environment for 
statistical computing version 3.1.3 (open source, www.r-project.org) and the “rpart” 
package. Two-sided statistical testing at the 0.05 level of significance was used for all 
analyses. 
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3.3 Variables 
A number of factors were used in analyses including age, clinical data on the tumour 
(stage, total Gleason score), treatment (EBRT versus other, hormone therapy), and 
biochemical data (pretreatment PSADT, pre-biochemical failure PSADT, TTBF, nadir 
PSA, months to nadir PSA). A detailed variable list of the GUROC ProCaRS database 
may be found in Appendix II. Overall survival was defined as survival after BF. 
PSADT Calculations 
One of the factors found in the literature to be correlated with overall survival in prostate 
cancer patients who have experienced biochemical failure is PSA doubling time 
(PSADT). Three versions of PSADT were calculated each based on two PSA values with 
corresponding times: 
1) Pretreatment PSADT (“Pre-RT PSADT”), which is based on the last 2 PSA 
values (PSA1 and PSA2) before radiotherapy was administered 
2) Pre-BF PSADT (“PSADT Nadir-Last”), calculated using the nadir PSA 
(PSA3) and first PSA value before BF (PSA5), and finally 
3) Pre-BF PSADT (“PSADT Last-2”) based on the last 2 PSA values prior to BF 
(PSA4 and PSA5) 
PSADT was calculated by the natural log of 2 (0.693) divided by the slope of the 
relationship between the log of PSA and time between PSA measurement for each patient 
(Pound et al. 1999; Patel et al. 1997).  
Using Figure 3 for guidance on PSADT calculations: 
1) 𝑃𝑟𝑒 − 𝑅𝑇𝑃𝑆𝐴𝐷𝑇 =
𝐿𝑜𝑔 2
𝐿𝑜𝑔 (𝑃𝑆𝐴2) − 𝐿𝑜𝑔(𝑃𝑆𝐴1)
(𝑇𝑖𝑚𝑒2 − 𝑇𝑖𝑚𝑒1)
 
2) 𝑃𝑆𝐴𝐷𝑇 𝑁𝑎𝑑𝑖𝑟 − 𝐿𝑎𝑠𝑡 =
𝐿𝑜𝑔 2
𝐿𝑜𝑔 (𝑃𝑆𝐴5) − 𝐿𝑜𝑔(𝑃𝑆𝐴3)
(𝑇𝑖𝑚𝑒5 − 𝑇𝑖𝑚𝑒3)
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3) 𝑃𝑆𝐴𝐷𝑇 𝐿𝑎𝑠𝑡 − 2 =
𝐿𝑜𝑔 2
𝐿𝑜𝑔 (𝑃𝑆𝐴5) − 𝐿𝑜𝑔(𝑃𝑆𝐴4)
(𝑇𝑖𝑚𝑒5 − 𝑇𝑖𝑚𝑒4)
 
Each PSADT calculation was evaluated using separate multivariable models. In some 
cases PSADT could not be calculated either due to insufficient data or due to undefined 
values (i.e. no change in PSA values). Figure 4 provides an example of a PSA follow-up 
profile of a patient with pretreatment PSADT that provides a negative value. Additional 
PSADT variables were obtained by excluding PSADT with negative and missing values. 
PSADT was kept as a continuous variable in univariable, multivariable, and RPA to 
determine the optimal PSADT cutoff level. Hazard ratios for PSADT were reported at 3 
month intervals along with 95% CI. Additionally, PSADT was categorized into PSADT 
less than 6 months, between 6-12 months, and 12 months and greater, for univariable and 
multivariable analysis. 
Radiation Treatment 
While the GUROC ProCaRS database provides 5 categories of radiation treatments 
(HDR-BT only, HDR-BT+EBRT, LDR-BT only, LDR-BT+ EBRT, and finally EBRT 
only), treatments were recategorized into 2 overall categories: EBRT only versus Other. 
Apart from EBRT only, the number of patients who have BF and were treated with BT 
were quite low, as is demonstrated in Table 7.  
Total Gleason Score 
Gleason score was initially comprised of 9 individual categories (2-10), however for 
univariable and multivariable analyses this was modelled as 4 categories. Gleason score 
values of 6 and 7 remained unchanged, but those between 2 and 5 and those between 8 
and 10 formed the remaining 2 categories. 
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Figure 3: PSA values for calculating PSADT 
1) 𝑃𝑟𝑒 − 𝑅𝑇𝑃𝑆𝐴𝐷𝑇 =
𝐿𝑜𝑔 2
𝐿𝑜𝑔 (𝑃𝑆𝐴2) − 𝐿𝑜𝑔(𝑃𝑆𝐴1)
(𝑇𝑖𝑚𝑒2 − 𝑇𝑖𝑚𝑒1)
 
                                  =
𝐿𝑜𝑔 2
𝐿𝑜𝑔 (5.00) − 𝐿𝑜𝑔(4.40)
(−1.58 − (−2.76))
 
           =
0.693
1.61 − 1.48
1.18
 
=
0.693
0.13
1.18
 
=
0.693
0.11
 
=  6.30 
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Figure 4: Example of PSA Follow-Up Profile Depicting Negative Pre-treatment 
PSADT 
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Chapter 4 : Results 
4.1 Descriptive Analysis 
Various descriptive statistics for all patients, with and without BF are presented in Tables 
6 to 8. Among the 1246 patients with BF included in analysis, there were 486 deaths 
overall. Of these deaths, 255 (52.27%) were deaths due to prostate cancer, while deaths 
from other causes or not otherwise specified were comprised of 197 (40.53%) and 34 
(7.00%), respectively. In contrast, of patients without BF, there were 744 deaths overall 
of which only 18 (2.42%) were deaths due to prostate cancer. 83.87% of deaths were due 
to other causes within these patients.  
The mean age of patients with BF was 68.90 ± 7.17 years. The mean time after RT to BF 
was 48.14 ± 30.79 months, and the mean time from BF to death was 52.39 ± 38.35 
months. Median baseline PSA for patients with BF was 10.00 ng/mL (IQR= 6.67- 17.00). 
Of those that did not have BF, median baseline PSA was 6.40 ng/mL (IQR= 4.70- 8.90). 
13.78% of BF patients had a Gleason score between 8 to 10, whereas 3.29% of patients 
without BF had a Gleason score between 8 to 10. In addition, a greater proportion of 
patients who had PSA recurrence had T3 and T4 tumours (23.13% and 2.12%, 
respectively), when compared to patients without BF (5.43% and 0.36%, respectively).  
According to D’Amico risk stratification, 18.55% of BF patients were of low risk, while 
51.79% of patients without BF were low risk. A greater proportion of BF patients were of 
high risk when compared to patients without BF (43.63% and 12.74%, respectively). 
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Table 6: Patient Clinical Characteristics 
Characteristic n All Patients 
(N=7974) 
Patients with 
Biochemical 
Failure 
(N=1246) 
Patients 
without 
Biochemical 
Failure 
(N=6728) 
Age- mean± SD 
(min to max) 
7970 67±7 
(34 to 88) 
69±7 
(43 to 88) 
66±7 
(34 to 86) 
Baseline PSA 
(ng/mL)- median 
(IQR: Q1, Q3) 
7844 6.80 
(4.90, 9.70) 
10.00 
(6.67, 17.00) 
6.40 
(4.70, 8.90) 
Centre- n(%) 
BCCA Registry 
Laval 
McGill 
PMH 
7974  
3771 (47.29) 
2257 (28.30) 
194 (2.43) 
1752 (21.97) 
 
858 (68.86) 
115 (9.23) 
13 (1.04) 
260 (20.87) 
 
2913 (43.30) 
2142 (31.84) 
181 (2.69) 
2913 (43.30) 
T stage- n(%) 
1 
2 
3 
4 
7860 
 
 
3553 (45.20) 
3613 (45.97) 
644 (8.19) 
50 (0.64) 
 
297 (24.19) 
621 (50.57) 
284 (23.13) 
26 (2.12) 
 
3256 (49.22) 
2986 (45.14) 
354 (5.35) 
19 (0.29) 
Gleason Score- 
n(%) 
2 
3 
4 
5 
6 
7 
8 
9 
10 
7839  
 
17 (0.22) 
39 (0.50) 
252 (3.21) 
577 (7.36) 
4267 (54.43) 
2301 (29.35) 
229 (2.92) 
151 (1.93) 
6 (0.08) 
 
 
3 (0.25) 
9 (0.74) 
43 (3.52) 
151 (12.38) 
381 (31.23) 
465 (38.11) 
100 (8.20) 
64 (5.25) 
4 (0.33) 
 
 
14 (0.21) 
30 (0.45) 
209 (3.16) 
426 (6.44) 
3886 (58.71) 
1836 (27.74) 
129 (1.95) 
87 (1.31) 
2 (0.03) 
Positive Cores 
greater or equal 
to 50%- n(%) 
4475  
1686 (37.68) 
n=780 
430 (55.13) 
n=3695 
1256 (33.99) 
Bilateral Biopsy 
Status- n(%) 
N/A 
Negative 
Positive 
Unknown 
2999  
 
30 (1.00) 
1725 (57.52) 
1243 (41.45) 
1 (0.03) 
 
 
1 (0.14) 
351 (48.82) 
367 (51.04) 
0 (0.00) 
 
 
29 (1.27) 
1374 (60.26) 
876 (38.42) 
1 (0.04) 
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Table 7: Patient Treatment Characteristics 
Characteristic n All Patients 
(n=7974) 
Patients with 
Biochemical 
Failure 
(n=1246) 
Patients 
without 
Biochemical 
Failure 
(n=6728) 
Radiation Type- 
n(%) 
Brachy(HDR)+EBRT 
Brachy(LDR)+EBRT 
Brachy(HDR) only 
Brachy(LDR) only 
EBRT only 
7974  
 
711(8.92) 
52(0.65) 
26(0.33) 
4508(56.53) 
2677(33.57) 
 
 
36(2.89) 
7(0.56) 
0(0.00) 
228(18.30) 
975(78.25) 
 
 
675 (10.03) 
45 (0.67) 
26 (0.39) 
4280 (63.61) 
1702 (25.30) 
RT Start Year- n(%) 
1994 to 1999 
2000 to 2002 
2003 to 2005 
2006 to 2010 
7973  
1953 (24.50) 
1973 (24.75) 
2238 (28.07) 
1809 (22.69) 
 
727 (58.35) 
276 (22.15) 
155 (12.44) 
88 (7.06) 
 
1226 (18.23) 
1697 (25.23) 
2083 (30.96) 
1721 (25.58) 
EBRT- n(%) 7974 3440 (43.14) 1018 (81.70) 2422 (36.00) 
EBRT: Dose > 70 Gy- 
n(%) 
3440 719 (20.90) 197 (19.35) 522 (21.55) 
EBRT: Dose (Gy)- 
mean± SD (min to 
max) 
3439 63.32±11.78 
(19.00 to 79.80) 
66.73±7.70 
(40.00 to 
79.80) 
61.89±12.86 
(19.00 to 
79.80) 
EBRT: Number of 
Fractions- mean± SD 
(min to max) 
2838 33.17±6.35 
(10.00 to 42.00) 
33.38±5.66 
(20.00 to 
42.00) 
33.05±6.69 
(10.00 to 
42.00) 
EBRT: Dose per 
Fraction (cGy)- 
mean± SD (min to 
max) 
2838 208±29 
(179 to 300) 
205±24 
(179 to 300) 
210±32 
(180 to 300) 
EBRT: Biologic 
Equivalent Dose 
(Gy)- mean± SD (min 
to max) 
2838 137.50±13.56 
(37.05 to 
165.00) 
135.92±10.38 
(85.50 to 
165.00) 
138.35±14.92 
(37.05 to 
165.00) 
LDR- n(%) 7974 4560 (57.19) 235 (18.86) 4325 (64.28) 
LDR: Dose (Gy)- 
mean± SD (min to 
max) 
4560 153.88±13.20 
(89.00 to 
217.00) 
154.35±13.12 
(104.00 to 
193.00) 
153.85±13.21 
(89.00 to 
217.00) 
HDR- n(%) 7974 737 (9.24) 36 (2.89) 701 (10.42) 
HDR: Dose- mean± 
SD (min to max) 
727 17.04±3.97 
(10.00 to 38.00) 
16.51±4.49 
(10.00 to 
20.00) 
17.06±3.94 
(10.00 to 
38.00) 
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Brachytherapy- n(%) 7974 5297 (66.43) 271 (21.75) 5026 (74.70) 
Hormone Therapy-
n(%) 
7974 2999 (37.61) 551 (44.22) 2448 (36.39) 
Adjuvant Hormone 
Therapy Duration-
mean± SD (min to 
max) 
2660 10.45±14.37 
(0.10 to 143.74) 
15.04±21.00 
(0.23 to 
142.82) 
9.31±11.91 
(0.10 to 
143.74) 
D’Amico- n(%) 
  Low 
  Intermediate 
  High 
7850  
3653 (46.54) 
2814 (35.85) 
1383 (17.62) 
 
230 (18.55) 
469 (37.82) 
541 (43.63) 
 
3423 (51.79) 
2345 (35.48) 
842 (12.74) 
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Table 8: Patient Outcome and Biochemical Characteristics 
Characteristic n All Patients 
(n=7974) 
Patients with 
Biochemical 
Failure (n=1246) 
Patients 
without 
Biochemical 
Failure 
(n=6728) 
Nadir PSA (ng/mL)- 
mean± SD (min to max) 
7706 0.67±4.08 
(0.00 to 
291.90) 
1.64±9.41 
(0.00 to 291.90) 
0.45±0.64 
(0.00 to 9.15) 
Time to Nadir 
(months)- mean± SD 
(min to max) 
7706 13.09±12.29 
(0.00 to 
132.27) 
13.56±10.24 
(0.00 to 105.13) 
12.99±12.69 
(0.00 to 
132.27) 
Clinical/Pathology 
confirmed Local 
Relapse- n(%) 
7974  
381 (4.78) 
 
 
319 (25.60) 
 
62 (0.92) 
Dead- n(%) 7974 1230 (15.43) 486 (39.00) 744 (11.06) 
Cause of Death-n(%) 
NOS 
Other 
Of Disease 
1230  
136 (11.06) 
821 (66.75) 
273 (22.20) 
 
34 (7.00) 
197 (40.53) 
255 (52.47) 
 
102 (13.71) 
624 (83.87) 
18 (2.42) 
Death 5 yr- n(%) 7974 453 (5.68) 131 (10.51) 322 (4.79) 
Prostate Cancer Death 
≤5 years-n(%) 
7974 106 (1.33) 94 (7.54) 12 (0.18) 
TTBF- mean± SD (min 
to max) 
1246 
-- 
48.14±30.79 
(1.45 to 185.07) 
-- 
Time from BF to 
Death- mean± SD (min 
to max) 
1246 
-- 
52.39±38.35 
(0.00 to 161.91) -- 
PreRT PSADT- mean± 
SD (min to max) 
532 
-- 
5.57±91.15 
(-218.15 to 
1862.62) 
-- 
PreRT PSADT No Neg- 
mean± SD (min to max) 
189 
-- 
37.75±143.97 
(0.02 to 1862.62) 
-- 
PreBF Nadir and Last 
PSADT- mean± SD (min 
to max) 
1036 
-- 
20.51±86.03 
(-1118.51 to 
1751.45) 
-- 
PreBF Nadir and Last 
PSADT No Neg- mean± 
SD (min to max) 
1001 
-- 
25.92±73.52 
(0.08 to 1751.45) -- 
PreBF Last2 PSADT- 
mean± SD (min to max) 
1120 
-- 
7.51±55.19 
(-820.16 to 
383.88) 
-- 
PreBF Last2 PSADT No 945 -- 18.20±29.87 -- 
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Neg- mean± SD (min to 
max) 
(0.08 to 383.88) 
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Descriptive statistics by Training and Validating group for clinical characteristics of 
patients within the GUROC ProCaRS database with BF are provided in Table 9. Table 10 
describes patient treatment characteristics for each group (Training and Validating), 
while Table 11 provides descriptive statistics on patient outcomes for each group 
(Training and Validating). 
Chi-square tests and two-sample t-tests for categorical and continuous variables found 
that the Training and Validating groups were not significantly different in patient 
characteristics, treatment characteristics, patient outcome and biochemical data. All p-
values were found to be greater than 0.05. No significant difference in overall survival 
was observed comparing Training and Validating sets based on Kaplan-Meier estimates 
as shown in Figure 5 (Log-Rank: p=0.34). 
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Table 9: Clinical Characteristics of Patients with Biochemical Failure by Group 
Characteristic n Training 
(n=831) 
Validating 
(n=415) 
Total 
Age- mean± SD (min 
to max) 
1246 69±7 
(45 to 88) 
69±7 
(43 to 84) 
1245 
Baseline PSA 
(ng/mL)- median 
(IQR: Q1, Q3) 
1246 10.40 
(6.78, 17.80) 
9.50 
(6.40, 16.00) 
1234 
Centre- n(%) 
BCCA Registry 
Laval 
McGill 
PMH 
1246  
564 (67.87) 
82 (9.87) 
8 (0.96) 
177 (21.30) 
 
294 (70.84) 
33 (7.95) 
5 (1.20) 
83 (20.00) 
 
858 
115 
13 
260 
Tstage- n(%) 
1 
2 
3 
4 
1228  
196 (23.90) 
423 (51.59) 
185 (22.56) 
16 (1.95) 
 
101 (24.75) 
198 (48.53) 
99 (24.26) 
10 (2.45) 
 
297 
621 
284 
26 
Gleason Score-n(%) 
2 
3 
4 
5 
6 
7 
8 
9 
10 
1220  
1 (0.12) 
6 (0.73) 
29 (3.55) 
97 (11.86) 
253 (30.93) 
322 (39.36) 
68 (8.31) 
40 (4.89) 
2 (0.24) 
 
2 (0.50) 
3 (0.75) 
14 (3.48) 
54 (13.43) 
128 (31.84) 
143 (35.57) 
32 (7.96) 
24 (5.97) 
2 (0.50) 
 
3 
9 
43 
151 
381 
465 
100 
64 
4 
Positive Cores 
greater or equal to 
50%- n(%) 
780 293 (56.89) 137 (51.70) 430 
Bilateral Biopsy 
Status- n(%) 
N/A 
Negative 
Positive 
719  
 
1 (0.21) 
233 (48.64) 
245 (51.15) 
 
 
0 (0.00) 
118 (49.17) 
122 (50.83) 
 
 
1 
351 
367 
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Table 10: Treatment Characteristics of Patients with Biochemical Failure by Group 
Characteristic n Training 
(n=831) 
Validating 
(n=415) 
Total 
Radiation Type-n(%) 
Brachy(HDR)+EBRT 
Brachy(LDR)+EBRT 
Brachy(HDR) only 
Brachy(LDR) only 
EBRT only 
1246  
25 (3.01) 
6 (0.72) 
-- 
150 (18.05) 
650 (78.22) 
 
11 (2.65) 
1 (0.24) 
-- 
78 (18.80) 
325 (78.31) 
 
36 
7 
-- 
228 
975 
RT Start Year- n(%) 
1994 to 1999 
2000 to 2002 
2003 to 2005 
2006 to 2010 
1246  
479 (57.64) 
184 (22.14) 
108 (13.00) 
60 (7.22) 
 
248 (59.76) 
92 (22.17) 
47 (11.33) 
28 (6.75) 
 
727 
276 
155 
88 
EBRT- n(%) 1246 681 (81.95) 337 (81.20) 1018 
EBRT Dose >70 Gy- 
n(%) 
1018 135 (19.82) 62 (18.40) 197 
EBRT Dose (Gy)- 
mean± SD (min to 
max) 
1246 6673±790 
(4000 to 7980) 
6673±729 
(4000 to 7980) 
1018 
EBRT Fractions- mean± 
SD (min to max) 
1246 33.44±5.71 
(20.00 to 42.00) 
33.26±5.57 
(20.00 to 
42.00) 
992 
EBRT Dose per 
Fraction (cGy) - mean± 
SD (min to max) 
1246 205±24 
(179 to 300) 
206±25 
(180 to 300) 
992 
EBRT Biologic 
Equivalent Dose (Gy) - 
mean± SD (min to 
max) 
1246 136.04±10.61 
(85.50 to 
165.00) 
135.67±9.93 
(85.50 to 
155.61) 
992 
LDR- n(%) 1246 156 (18.77) 79 (19.04) 235 
LDR Dose (Gy)- mean± 
SD (min to max) 
1246 154.35±14.09 
(104.00 to 
193.00) 
154.37±11.04 
(136.00 to 
183.00) 
235 
HDR- n(%) 1246 25 (3.01) 11 (2.65) 36 
HDR Dose- mean± SD 
(min to max) 
1246 1742±418 
(1000 to 2000) 
1455±472 
(1000 to 2000) 
35 
Brachytherapy- n(%) 1246 181 (21.78) 90 (21.69) 271 
Hormone Therapy- 
n(%) 
1246 384 (46.21) 167 (40.24) 551 
Adjuvant Hormone 
Therapy Duration- 
mean± SD (min to 
1246 13.55±17.46 
(0.23 to 100.96) 
18.45±27.22 
(0.23 to 
142.82) 
531 
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max) 
D’Amico 
  Low 
  Intermediate 
  High 
1240  
144 (17.39) 
321 (38.77) 
363 (43.84) 
 
86 (20.87) 
148 (35.92) 
178 (43.20) 
 
230 
469 
541 
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Table 11: Outcome and Biochemical Characteristics of Patients with Biochemical 
Failure by Group 
Characteristic n Training (n=831) Validating (n=415) 
Nadir PSA (ng/mL) - 
mean± SD (min to max) 
1246 1.45±5.14 
(0.00 to 130.00) 
2.02±14.57 
(0.01 to 291.90)  
Time to Nadir 
(months) - mean± SD 
(min to max) 
1246 13.25±9.99 
(0.00 to 105.13) 
14.17±10.70 
(0.00 to 99.78) 
Clinical/Pathology 
confirmed Local 
Relapse- n(%) 
319 217 (26.11) 102 (24.58) 
Dead- n(%) 486 314 (37.79) 172 (41.45) 
Cause of Death-n(%) 
NOS 
Other 
Of Disease 
486  
17 (5.41) 
131 (41.72) 
166 (52.87) 
 
17 (9.88) 
66 (38.37) 
89 (51.74) 
Death 5 yr- n(%) 131 79 (9.51) 52 (12.53) 
Time from 
Biochemical Failure to 
Death- mean± SD (min 
to max) 
1246 52.71±37.72 
(0.00 to 156.88) 
51.76±39.62 
(0.00 to 161.91) 
TTBF- mean± SD (min 
to max) 
1246 47.86±30.25 
(1.45 to 185.07) 
48.69±31.87 
(4.60 to 153.33) 
CRS (Prostate Cancer 
Death)- n(%) 
255 166 (19.98) 89 (21.45) 
Biochemical Failure ≤5 
years- n(%) 
862 580 (69.80) 282 (67.95) 
PreRT PSADT- mean± 
SD (min to max) 
T:354 
V: 178 
7.39±109.06 
(-218.15 to 1862.62)  
1.96±34.43 
(-95.64 to 194.38) 
PreRT PSADT No Neg- 
mean± SD (min to max) 
T: 134 
V: 55 
41.61±168.41 
(0.02 to 1862.62)  
28.34±46.67 
(0.89 to 194.38) 
PreBF Nadir and Last 
PSADT- mean± SD (min 
to max) 
T: 693 
V:343 
22.09±96.02 
(-1118.51 to 1751.45)  
17.31±61.05 
(-398.79 to 451.10) 
PreBF Nadir and Last 
PSADT No Neg- mean± 
SD (min to max) 
T: 672 
V: 329 
26.48±84.63 
(0.08 to 1751.45) 
24.77±42.72 
(1.02 to 451.10) 
PreBF Last2 PSADT- 
mean± SD (min to max) 
T: 745 
V: 375 
7.51±56.10 
(-820.16 to 383.88) 
7.52±53.40 
(-648.63 to 334.75) 
PreBF Last2 PSADT No 
Neg- mean± SD (min to 
max) 
T: 633 
V: 312 
18.00±29.09 
(0.08 to 383.88) 
18.60±31.46 
(0.55 to 334.75) 
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Figure 5: Post-Biochemical Failure Survival and Patients at Risk in Training and 
Validating Dataset (Log-Rank: p=0.34). 
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4.2 Univariable and Multivariable Analyses 
Table 12 provides the results of univariable and multivariable analysis on the Training set 
(N=831). Variables included in analysis were age, baseline PSA, T stage, total Gleason 
score, hormone therapy, radiation treatment, nadir PSA, time to nadir, PSADT and 
TTBF. PSADT was assessed as a continuous and categorical variable in Table 12 and 13 
respectively.  
Upon univariable analysis a number of factors including age, T stage, higher Gleason 
scores, hormone therapy, radiation treatment, and nadir PSA were found to be 
independent predictors for overall survival.  
The first multivariable model with Pre-RT PSADT analyzing OS after BF produced age, 
baseline PSA, T stage, hormone therapy, nadir PSA, and TTBF as significant predictors. 
The second model with PSADT Nadir-Last, identified similar factors except for nadir 
PSA which was excluded. Radiation treatment and Gleason score were additionally found 
as significant predictors for OS within this model. The final model (PSADT Last-2) 
found that all variables included in the model, except for PSADT Last-2 and time to 
nadir, were significant predictors of OS.  
Multivariable analyses using PSADT as a categorical variable offered similar results to 
the models using PSADT as a continuous variable, however pre-BF PSADT (Nadir-Last, 
and Last-2), were found to be significant predictors of OS after BF. 
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Table 12: Univariable and Multivariable Regression Models for Overall Survival 
among Patients with Biochemical Failure with PSADT as a Continuous Variable 
 Training Cohort (n=831) 
Univariable Multivariable 1 
(Pre-RT PSADT) 
Multivariable 2 
(PSADT Nadir-Last) 
Multivariable 3 
(PSADT Last2) 
Independent 
Variables 
Hazard 
Ratio  
(95% CI) 
p-value Hazard 
Ratio  
(95% CI) 
p-
value 
Hazard 
Ratio 
(95% CI) 
p-
value 
Hazard 
Ratio  
(95% CI) 
p-
value 
Age per 1 
year increase 
1.03 
(1.01, 
1.04) 
<0.01 
 
1.06 
(1.01, 
1.10) 
0.01 1.03 
(1.01, 
1.06) 
0.01 1.03 
(1.002, 
1.05) 
0.03 
Baseline PSA 
per 1 ng/mL 
increase 
1.00 
(1.00, 
1.01) 
0.28 0.98 
(0.96, 
0.995) 
0.02 0.99 
(0.98, 
1.00) 
0.04 0.99 
(0.98, 
0.999) 
0.03 
T stage 
2 vs. 1 
 
 
3 vs. 1 
 
 
4 vs. 1 
 
1.41 
(0.98, 
2.04) 
2.34 
(1.61, 
3.41) 
3.81 
(2.02, 
7.19) 
 
0.07 
 
 
<0.01 
 
 
<0.01 
 
1.59 
(0.60, 
4.18) 
2.42 
(0.89, 
6.59) 
9.60 
(1.90, 
48.42) 
 
0.35 
 
 
0.08 
 
 
<0.01 
 
1.24 
(0.82, 
1.89) 
1.65 
(1.05, 
2.59) 
3.30 
(1.30, 
8.38) 
 
0.30 
 
 
0.03 
 
 
0.01 
 
1.33 
(0.86, 
2.05) 
1.82 
(1.15, 
2.90) 
3.08 
(1.28, 
7.43) 
 
0.20 
 
 
0.01 
 
 
0.01 
Total Gleason 
Score 
6 vs. 2 to 5 
 
 
7 vs. 2 to 5 
 
 
8- 10 vs. 2 
to 5 
 
 
0.99 
(0.68, 
1.44) 
1.41 
(1.02, 
1.96) 
2.52 
(1.75, 
3.62) 
 
 
0.97 
 
 
0.04 
 
 
<0.01 
-- -- 
 
 
1.07 
(0.70, 
1.64) 
1.19 
(0.80, 
1.75) 
1.87 
(1.19, 
2.95) 
 
 
0.74 
 
 
0.39 
 
 
<0.01 
 
 
1.06 
(0.68, 
1.65) 
1.15 
(0.77, 
1.70) 
1.97 
(1.26, 
3.10) 
 
 
0.81 
 
 
0.50 
 
 
<0.01 
Hormone 
Therapy 
Yes vs. No 
1.46 
(1.16, 
1.82) 
<0.01 2.02 
(1.14, 
3.60) 
0.02 1.46 
(1.09, 
1.97) 
0.01 1.48 
(1.09, 
2.00) 
0.01 
Radiation 
Treatment 
EBRT only vs. 
other 
0.23 
(0.13, 
0.42) 
<0.01 
-- -- 
0.44 
(0.23, 
0.84) 
0.01 0.38 
(0.19, 
0.74) 
<0.01 
Nadir PSA per 
1 ng/mL 
increase 
1.03 
(1.01, 
1.04) 
<0.01 1.07 
(1.02, 
1.12) 
<0.01 
-- -- 
1.03 
(1.02, 
1.05) 
<0.01 
Time to Nadir 
per month 
increase 
1.01 
(1.00, 
1.02) 
0.07 
-- -- -- -- -- -- 
PreRT PSADT 
per 3 month 
increase 
0.99 
(0.97, 
1.01) 
0.21 
-- -- -- -- -- -- 
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NoNeg 
PreBF Nadir-
Last PSADT 
per 3 month 
increase 
NoNeg 
0.996 
(0.99, 
1.01) 
0.44 
-- -- -- -- -- -- 
PreBF Last2 
PSADT per 3 
month 
increase 
NoNeg 
1.002 
(0.99, 
1.02) 
 
0.79 
-- -- -- -- -- -- 
TTBF per 
month 
increase 
1.00 
(1.00, 
1.01) 
0.07 1.02 
(1.01, 
1.03) 
<0.01 1.01 
(1.003, 
1.02) 
<0.01 1.01 
(1.004, 
1.02) 
<0.01 
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Table 13: Univariable and Multivariable Regression Models for Overall Survival 
among Patients with Biochemical Failure with PSADT as a Categorical Variable 
 Training Cohort (n=831) 
 Univariable Multivariable 1 
(Pre-RT PSADT) 
Multivariable 2 
(PSADT Nadir-
Last) 
Multivariable 3 
(PSADT Last2) 
Independent 
Variables 
Hazard 
Ratio  
(95% CI) 
p-
value 
Hazard 
Ratio  
(95% CI) 
p-
value 
Hazard 
Ratio 
(95% CI) 
p-
value 
Hazard 
Ratio  
(95% CI) 
p-
value 
Age per 1 year 
increase 
1.03 
(1.01, 
1.04) 
<0.01 
 
1.06 
(1.01, 
1.10) 
0.01 1.03 
(1.01, 
1.06) 
0.01 1.03 
(1.003, 
1.05) 
0.03 
Baseline PSA per 1 
ng/mL increase 
1.00 
(1.00, 
1.01) 
0.28 0.98 
(0.96, 
0.995) 
0.02 0.99 
(0.98, 
0.998) 
0.02 0.98 
(0.97, 
0.995) 
<0.01 
 
T stage 
2 vs. 1 
 
 
3 vs. 1 
 
 
4 vs. 1 
 
1.41 
(0.98, 
2.04) 
2.34 
(1.61, 
3.41) 
3.81 
(2.02, 
7.19) 
 
0.07 
 
 
<0.01 
 
 
<0.01 
 
1.59 
(0.60, 
4.18) 
2.42 
(0.89, 
6.59) 
9.60 
(1.90, 
48.42) 
 
0.35 
 
 
0.08 
 
 
<0.01 
 
 
1.23 
(0.81, 
1.86) 
1.69 
(1.08, 
2.64) 
3.57 
(1.38, 
9.23) 
 
0.33 
 
 
0.02 
 
 
<0.01 
 
 
1.36 
(0.88, 
2.10) 
1.73 
(1.08, 
2.76) 
2.97 
(1.21, 
7.27) 
 
0.17 
 
 
0.02 
 
 
0.02 
Total Gleason Score 
6 vs. 2 to 5 
 
 
7 vs. 2 to 5 
 
 
8- 10 vs. 2 to 5 
 
0.99 
(0.68, 
1.44) 
1.41 
(1.02, 
1.96) 
2.52 
(1.75, 
3.62) 
 
0.97 
 
 
0.04 
 
 
<0.01 
-- -- -- -- 
 
1.09 
(0.70, 
1.70) 
1.13 
(0.76, 
1.69) 
1.86 
(1.18, 
2.94) 
 
0.71 
 
 
0.55 
 
 
<0.01 
 
Hormone Therapy 
Yes vs. No 
1.46 
(1.16, 
1.82) 
<0.01 2.02 
(1.14, 
3.60) 
0.02 
-- -- 
1.41 
(1.04, 
1.92) 
0.03 
Radiation Treatment 
EBRT only vs. other 
0.23 
(0.13, 
0.42) 
<0.01 
-- -- 
0.35 
(0.18, 
0.66) 
<0.01 
 
0.27 
(0.13, 
0.55) 
<0.01 
 
Nadir PSA per 1 
ng/mL increase 
1.03 
(1.01, 
1.04) 
<0.01 1.07 
(1.02, 
1.12) 
<0.01 
 -- -- 
1.03 
(1.02, 
1.04) 
<0.01 
 
Time to Nadir per 
month increase 
1.01 
(1.00, 
1.02) 
0.07 
-- -- -- -- -- -- 
Pre-RT PSADT NoNeg 
6-12 months vs. 0-6 
months 
 
 
0.71 
(0.38, 
1.33) 
 
0.28 
 
 
-- -- -- -- -- -- 
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12+ months vs. 0-6 
months 
0.69 
(0.40, 
1.21) 
0.19 
PreBF Nadir-Last 
PSADT NoNeg 
6-12 months vs. 0-6 
months 
 
12+ months vs. 0-6 
months 
 
 
0.82 
(0.56, 
1.19) 
0.73 
(0.52, 
1.01) 
 
 
0.29 
 
 
0.06 
-- -- 
 
 
0.63 
(0.42, 
0.94) 
0.39 
(0.26, 
0.59) 
 
 
0.02 
 
 
<0.01 
 
-- -- 
PreBF Last2 PSADT 
NoNeg 
6-12 months vs. 0-6 
months 
 
12+ months vs. 0-6 
months 
 
 
0.60 
(0.43, 
0.85) 
0.76 
(0.56, 
1.04) 
 
 
<0.01 
 
 
0.08 
-- -- -- -- 
 
 
0.43 
(0.29, 
0.63) 
0.48 
(0.32, 
0.70) 
 
 
<0.01 
 
 
<0.01 
 
TTBF per month 
increase 
1.00 
(1.00, 
1.01) 
0.07 1.02 
(1.01, 
1.03) 
<0.01 
 
1.01 
(1.01, 
1.02) 
<0.01 
 
1.01 
(1.01, 
1.02) 
<0.01 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
 
 
4.3 Recursive Partitioning Analysis 
A recursive decision tree of patients using the Training set was created to provide a post-
BF risk stratification model. The main outcome for model building was 5 year overall 
survival after BF. Both pre-treatment and post-treatment factors were included in the 
predictive model and were identified from multivariable analyses and from literature 
review. Pre-treatment factors included age, baseline PSA, T stage and total Gleason 
score. Post-treatment factors included nadir PSA, time to nadir, TTBF, PSADT Nadir-
Last, and PSADT Last-2.  
The preliminary RPA model provided a tree with 7 terminal nodes as depicted in Figure 
6. TTBF ≥ 6.5 versus < 6.5 years was selected as the primary node. Secondary splits 
incorporated both PSADT definitions: Pre-BF PSADT Last-2 at approximately 5 months 
and Pre-BF PSADT Nadir-Last at 1 year. Third level predictors in the RPA were Gleason 
score (2-7 versus 8-10) and age at approximately 65 years. Downstream branches from 
Pre-BF PSADT Nadir-Last were trimmed as they were of smaller sample size and did not 
provide added value. 
From preliminary RPA, a 6-class risk group system was identified based on TTBF, Pre-
BF PSADT Nadir-Last and Pre-BF PSADT Last-2, Gleason score and age (Table 14). 
Survival at 5 years from the 6 risk groups were then estimated from Kaplan-Meier 
survival curves from the Training Cohort (Figure 7). While each risk group was 
comprised of differing prognostic factors and splits, Kaplan-Meier survival curves 
indicated that the 6 risk group categories could be replaced with a 2-class risk system to 
identify patients as either high risk or low risk for premature death. Specifically risk 
group 1 and 3 would make up patients at low risk, and risk groups 2, 4, 5 and 6 make up a 
high risk category (Figure 8). While risk group 6 indicated a single group at greater risk 
than the other risk groups, it was placed into the high risk category due to its small 
sample size. Figure 8 also presents the frequency of patients within the Training and 
Validating cohorts. Kaplan-Meier survival curves for the Validating Cohort can be seen 
in Figure 9.  
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Table 14: 6-Class Risk Group 
Risk 
Group 
 
1 TTBF < 6.5 years + Pre-BF PSADT Last-2 ≥ 5 months + Gleason score = 2-7 
2 TTBF < 6.5 years + Pre-BF PSADT Last-2 ≥ 5 months + Gleason score = 8-10 
3 TTBF < 6.5 years + Pre-BF PSADT Last-2 < 5 months +Age < 65 years 
4 TTBF < 6.5 years + Pre-BF PSADT Last-2 <5 months + Age ≥ 65 years 
5 TTBF ≥ 6.5 years + Pre-BF PSADT Nadir-Last ≥ 1 year 
6 TTBF ≥ 6.5 years + Pre-BF PSADT Nadir-Last < 1 year 
 
 
 
 
 
 
61 
 
 
 
 
Figure 6: Preliminary RPA Tree 
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Figure 7: Kaplan-Meier survival curves of 6 Risk Group categories in Training 
Cohort (Log-Rank: p<0.01). 
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Figure 8: Low and High Risk Groups from RPA after Trimming 
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Figure 9: Kaplan-Meier survival curves of 6 Risk Group categories in Validating 
Cohort (Log-Rank: p<0.01). 
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Results from the Training cohort demonstrated good differentiation between risk groups 
(Log-Rank: p<0.01) as shown in Figure 10. Figure 11 depicts corresponding results for 
the Validating cohort. Differences in each risk group between Training and Validating 
groups were also analyzed using the Log-Rank test (Figure 12 and 13). Patients defined 
as low risk in both Training and Validating groups were found to be significantly 
different in terms of OS (Log-Rank: p=0.01). This difference may be due small sample 
size. 81.03% and 69.44% of patients were censored in the Training and Validating 
cohorts respectively. In contrast, patients defined as high risk in both the Training and 
Validating cohorts were not significantly different from each other (Log-Rank: p=0.83). 
Approximately 45.12% of the patients were censored in both groups. Figures 14 to 19 
compare survival within each 6-class Risk Group between Training and Validating 
cohorts, and were not significantly different from each other.  
Based on Kaplan-Meier estimates for OS, high risk and low risk prognostic groups may 
be identified. Hazard ratios for high risk versus low risk for 5-year OS are reported in 
Table 15 with associated p-values, C-indices, and 95% confidence intervals (CI) for both 
Training and Validating Cohorts. The hazard ratios for 5-year OS for the Training cohort 
was 3.87 (95% CI: 2.64-5.68; p<0.01) and for the Validating cohort was 2.05 (95% CI: 
1.22-3.45; p<0.01). Table 16 presents similar data for 6-class risk groups. As model 
development was based on the Training dataset, this would explain for differences in 
hazard ratios between the Training and Validating set. Both 2-class risk groups and 6-
class risk groups still demonstrate the ability to identify groups of higher risk compared 
to lower risk. 
Table 17 presents all patients in both Training and Validating datasets in their respective 
risk groups created after RPA to determine if they were comparable given centre 
contributions. 
Median survival after BF among low risk patients were 6.91 years and 6.27 years in 
Training and Validating cohorts respectively. High risk patients had a median survival of 
4.62 and 4.13 years after BF in Training and Validating cohorts. 
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Figure 10: Kaplan-Meier Plot of 2 Risk Group Categories from Training Cohort 
(Log-Rank: p <0.01). 
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Figure 11: Kaplan-Meier Plot of 2 Risk Group Categories from Validating Cohort 
(Log-Rank: p<0.01). 
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Figure 12: Kaplan-Meier Plot of Low Risk Group for Training and Validating 
Cohorts (Log-rank: p=0.01). 
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Figure 13: Kaplan-Meier Plot for High Risk Group for Training and Validating 
Cohorts (Log-Rank: p=0.83).  
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Figure 14: Kaplan-Meier Plot for Risk Group 1 for Training and Validating 
Cohorts (Log-Rank: p=0.05). 
 
 
 
 
 
 
 
71 
 
 
 
 
Figure 15: Kaplan-Meier Plot for Risk Group 2 for Training and Validating 
Cohorts (Log-Rank: p=0.38). 
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Figure 16: Kaplan-Meier Plot for Risk Group 3 for Training and Validating 
Cohorts (Log-Rank: p=0.13). 
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Figure 17: Kaplan-Meier Plot for Risk Group 4 for Training and Validating 
Cohorts (Log-Rank: p=0.57). 
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Figure 18: Kaplan-Meier Plot for Risk Group 5 for Training and Validating 
Cohorts (Log-Rank: p=0.71). 
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Figure 19: Kaplan-Meier Plot for Risk Group 6 for Training and Validating 
Cohorts (Log-Rank: p=0.25). 
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Table 15: Hazard Ratio and associated 95% CI, p-value and c-index for Training 
and Validating Cohorts in 2-Class Risk Group 
 Hazard Ratio: 
High Risk vs. Low Risk 
95% CI p-value c-index 
Training 3.87 2.64 to 5.68 <0.01 0.69 
Validating 2.05 1.22 to 3.45 <0.01 0.60 
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Table 16: Hazard Ratio and associated 95% CI, p-value and c-index for Training 
and Validating Cohorts in 6-Class Risk Group 
Risk 
Group 
Training Validating 
Hazard 
Ratio 
95% CI p-
value 
c-
index 
Hazard 
Ratio 
95% CI p-
value 
c-
index 
2 vs. 1  3.30 1.82- 6.01 <0.01 
0.71 
1.34 0.55-3.26 0.52 
0.64 
3 vs. 1 1.49 0.63- 3.53 0.36 2.11 0.91-4.86 0.08 
4 vs. 1 3.77 2.29- 6.21 <0.01 2.76 1.25-6.11 0.01 
5 vs. 1 4.19 2.39- 7.35 <0.01 2.94 1.42- 6.11 <0.01 
6 vs. 1 41.07 16.31-
103.40 
<0.01 57.98 6.34-
531.51 
<0.01 
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Table 17 All Patients in Low and High Risk Category Groups by Centre 
Centre Low- n(%) High- n(%) 
British Columbia Cancer Agency 190 (81.90) 100 (85.47) 
L’Hotel Dieu de Québec 12 (6.03) 6 (5.13) 
McGill University Health Centre 0 (0.00) 0 (0.00) 
Princess Margaret Hospital 28 (12.07) 11 (9.40) 
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4.4 Evaluation of the Proportional Hazards Assumption 
Proportional hazards assumptions were first assessed graphically using log-minus-log 
survival plots for the 2 risk categories identified through RPA (Figure 20). Log-minus-
log survival plots for the 6-class risk groups are also depicted in Figure 21. Figures 22 to 
26 compares each risk group to Risk Group 1. Cross-over and lack of parallelism 
between the 2 categories was observed indicating possible violation of the proportional 
hazards assumption. Further assessment using the Kolmogrov test offered a less 
subjective evaluation of the proportional hazards assumption.  
The Kolmogrov test was assessed for all patients in Figure 27 for the 2-class Risk Group, 
and 29 to 34 for the 6-class Risk Group. This test was found to be significant (p<0.05) 
further suggesting a violation of proportional hazards assumptions. In the 6-class Risk 
Groups, using Risk Group 1 as the reference, Risk Group 3 is the only assessment 
indicating a potential violation of the proportional hazards assumption (p=0.04). 
Given the violation of proportional hazards, the 2 and 6-class risk group categories were 
assessed as time-dependent covariates to determine if the groups remained a significant 
predictor of survival for any time during the follow-up period. Results from the 
corresponding Cox proportional hazards regression model are shown in Table 18, 
indicating a likelihood ratio of p=0.02. Although the 2-class risk group was shown to 
violate the proportional hazards assumption, when assessed as a time-varying covariate, it 
continues to be a significant predictor of survival. Similarly, the corresponding regression 
model for the 6-class risk group produced a likelihood ratio of p<0.01, indicating the 6-
class risk group was also a significant predictor of survival when assessed as a time-
dependent covariate (Table 19). 
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Figure 20: Log-Minus-Log Survival Plots for All Patients within High and Low Risk 
Categories Identified through RPA 
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Figure 21: Log-Minus-Log Survival Plots for All Patients within 6-Class Risk 
Groups Identified through RPA 
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Figure 22: Log-Minus-Log Survival Plots for All Patients within Risk Group 1 and 
Risk Group 2 
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Figure 23: Log-Minus-Log Survival Plots for All Patients within Risk Group 1 and 
Risk Group 3 
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Figure 24: Log-Minus-Log Survival Plots for All Patients within Risk Group 1 and 
Risk Group 4 
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Figure 25: Log-Minus-Log Survival Plots for All Patients within Risk Group 1 and 
Risk Group 5 
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Figure 26: Log-Minus-Log Survival Plots for All Patients within Risk Group 1 and 
Risk Group 6 
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Figure 27: Supremum (Kolmogorov Test) for All Patients in 2-Class Risk Groups 
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Figure 28: Supremum (Kolmogorov Test) for All Patients in Risk Group 2 
compared to Risk Group 1 in 6-Class Risk Group 
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Figure 29: Supremum (Kolmogorov Test) for All Patients in Risk Group 3 
compared to Risk Group 1 in 6-Class Risk Group 
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Figure 30: Supremum (Kolmogorov Test) for All Patients in Risk Group 4 
compared to Risk Group 1 in 6-Class Risk Group 
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Figure 31: Supremum (Kolmogorov Test) for All Patients in Risk Group 5 
compared to Risk Group 1 in 6-Class Risk Group 
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Figure 32: Supremum (Kolmogorov Test) for All Patients in Risk Group 6 
compared to Risk Group 1 in 6-Class Risk Group 
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Table 18: 2-Class Risk Group as Time Varying Covariate 
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Table 19: 6-Class Risk Group as Time Varying Covariate 
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Chapter 5 : Discussion 
5.1 Limitations 
Much heterogeneity exists in PSADT definitions in the medical literature, which impairs 
the ability to make direct comparisons from univariable and multivariable analyses. Apart 
from how PSADT is calculated, it should be noted that not all patients will have positive 
values for PSADT. A proportion of patients will have PSADT values that are either 
negative, indicative of declining PSA over time in some instances, or undefined due to 
missing data or no change in PSA between time points. Depending on the definition(s) 
used, the proportion of patients unavailable for PSADT testing may vary within patient 
populations. PSADT also requires that patients have longer and regular follow-up data in 
order to have enough PSA measurements to allow for its calculation. For instance, the 
examination of Pre-RT PSADT required at least two PSA measurements available prior 
to start of radiotherapy, which was only available in a minority of patients. 
Final RPA classified patients using 2 definitions of pre-BF PSADT. While it would be 
preferable to have a classification identifying PSADT using one definition, the two 
PSADT calculations measure differently. Pre-BF PSADT calculated using the last 2 PSA 
values before BF (Last-2) gives an indication of the immediate kinetics prior to BF while 
pre-BF PSADT calculated using nadir PSA and the last PSA value prior to BF (Nadir-
Last), provide information on long-term PSA kinetics. This analysis demonstrated that 
both definitions are beneficial to predicting 5-year overall survival after biochemical 
failure.   
Random split-sample methods, where 2/3 of the original data are used to develop the 
model and 1/3 is used for validation, decreases statistical power for model development 
(Hendriksen et al. 2013). Although this method is not preferred, the GUROC ProCaRS 
database offers a large data set for evaluating and developing a model. In addition, this 
approach has been widely adopted within the (radiation) oncology literature for 
observational studies, particularly for the examination of survival outcomes, which 
allows for both graphical and quantitative comparisons (Lambin et al. 2013).   
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The division into Training and Validating cohorts allowed for the assessment of internal 
validity of the prediction model. Moderate or acceptable discriminatory ability of a model 
does not guarantee that it will perform similarly in a different group of patients. 
Therefore methods of external validation are necessary perhaps in different institutes or 
clinical settings. 
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5.2 Post-Treatment Risk Stratification 
Using data from a large database of RT patients, univariable and multivariable Cox 
proportional hazards regression analyses found a number of prognostic factors for OS 
after BF. Many of the factors in our study are similar to those found in literature with 
studies of smaller sample sizes. A summary of these variables may be found in Table 20. 
TTBF and PSADT were more consistently found in literature to be predictive of OS upon 
multivariable analysis. Other studies in literature found age to be a weak predictor or not 
significant among many other factors as well. This study, however, found that age, 
baseline PSA, higher T stage (T3 and T4 versus T1), higher Gleason score (8-10 versus 
2-5), hormone therapy, radiation therapy, nadir PSA, TTBF and shorter pre-BF PSADT 
(when categorized as <6, 6-12, and >12 month intervals) as significant (p<0.05) factors 
upon univariable and multivariable analyses based on the Training cohort.  
The benefit of using RPA and keeping variables as continuous is that cut-points will be 
based on optimal discrimination between groups, instead of categorization which creates 
information loss and may be potentially arbitrary and subjective. The choice of threshold 
of categorization is usually determined by data used for developing models and therefore 
makes the model unstable and less generalizable in its applications to other individuals 
(Hendriksen et al. 2013). Numerous cut-points for TTBF and PSADT in multivariable 
analyses have been observed in studies of varying sample sizes. PSADT has also been 
calculated in a number of different ways (Daskivich et al. 2006).  
The identification of a high risk group of patients with BF is of great importance in 
clinical research for prostate cancer. Prior to our study, there was no risk stratification for 
patients with BF for OS following date of BF, although one study has examined PCSS. 
This previous risk stratification predicting PCSS after BF was conducted using data from 
485 patients with BF in a clinical trial of 802 patients with locally advanced prostate 
cancer in Australia and New Zealand. This group used only PSADT and TTBF to explore 
its predictive accuracy (Steigler et al. 2012). 
Our study identified 6 unique patient groups based on TTBF, pre-BF PSADT (calculated 
with nadir and last, and last 2 PSA values), Gleason score, and age. Of these 6 groups, it 
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was found that 2 groups could be collapsed into a low risk group, and 4 groups could be 
combined as a high risk group based on their survival profiles. Hazard ratios from both 
Training and Validating cohorts confirmed that the high risk group identified patients 
who were at greater risk for death compared to patients identified as low risk. A study 
analyzing overall survival after BF among 154 patients demonstrated a median survival 
of 5.9 years after BF (Sandler et al. 2000). Using 2-class risk groups, low and high risk 
median survival could be determined. Median survival after BF among low risk patients 
were 6.91 years and 6.27 years in Training and Validating cohorts respectively. High risk 
patients had a median survival of 4.62 and 4.13 years after BF in Training and Validating 
sets.  
The c-index is commonly used to assess the predictive ability of statistical models. A c-
index of 0.5 implies that a model has no predictive ability, while a c-index of 1 implies 
perfect predictive ability. The 6-class risk stratification model gave rise to c-indices of 
0.71 and 0.64 Training and Validating cohorts. The 2-class model gave rise to c-indices 
of 0.69 and 0.60 respectively. These values describe a modest to acceptable predictive 
ability, when c-statistics are considered to have acceptable discrimination when between 
0.7 and 0.8 (Antonarakis et al. 2012). While collecting more variables for model 
development may have helped with predictive ability, the ProCaRS database consists of 
retrospectively collected data. 
Overall, the 2-class post-treatment risk stratification system, which has been internally 
validated, allows for the identification of a high risk and low risk of patients with BF 
after RT which will play an important role in guiding patient selection for future clinical 
trials and treatment decisions. 
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Table 20: Summary of Prognostic Factors of Overall Survival after Biochemical Failure among Patients with Radiotherapy as 
Primary Treatment 
Author, Year n T
re
at
m
en
t 
B
F 
d
ef
in
it
io
n
 
G
le
as
o
n
 S
co
re
 
T 
st
ag
e 
TT
B
F 
P
SA
D
T 
ag
e 
P
re
tr
ea
tm
en
t 
P
SA
 
P
SA
 n
ad
ir
 
Ti
m
e 
to
 n
ad
ir
 
C
o
m
o
rb
id
it
y 
sc
o
re
 
P
SA
 v
el
o
ci
ty
 
U
se
 o
f 
A
D
T 
af
te
r 
B
F 
B
ED
 
Wang, 2015 831 RT Nadir + 0.2ng/ml U 
M 
U 
M 
M 
U 
M 
U 
M 
M 
U 
M 
x   
U 
M 
 
Buyyounouski et al 
2012 
1722 RT Nadir + 0.2ng/ml 
x x M M   M      
Ko et al 2014 264 RT Nadir + 0.2ng/ml x x M x x x     x x 
Kim et al 2013 108 RT Nadir + 0.2ng/ml M x M  M x   M M x  
Sandler et al 2000 154 RT 3 consecutive rises x x x  x x x x     
Wo et al 2009 89 RT 2 consecutive rises ≥0.2ng/mL after 
nadir 
x x x  x    M M   
D’Amico et al 2006 81 RT  2 consecutive rises of at least 0.2ng/mL 
after PSA level >1.0ng/mL 
x x  M M x       
Where x indicates that a variable was investigated, U indicates a factor was significant upon univariable analysis, M indicates a factor 
was significant upon multivariable analysis 
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5.3 Future Directions 
Due to the small number of patients recorded with metastasis and death from prostate 
cancer in the GUROC ProCaRS database, this study focused analyses on OS following 
BF. Future studies focusing on post-treatment risk stratification for PCSS and MFS may 
provide useful classifications and comparisons for patients with BF after RT.  
While this study was internally validated, there exists the need to determine whether the 
prediction model performs well with other patients in different institutes. External 
validation provides information from the new population that differs from the population 
used for the development of the model. If the model performs well, then it indicates that 
it may be used in both populations. If not, further considerations can be made in updating 
the model, or assessing if the model is still able to contribute to predicting outcomes for 
patients adequately (Hendriksen et al. 2013; Collins et al. 2015).  
Given the results from univariable and multivariable analyses and RPA in identifying 
important prognostic factors for OS and a high risk group, the next steps would be to 
build a nomogram for prostate cancer patients with BF after RT and compare to proposed 
RPA risk groups.  Nomograms are often used in cancer prognosis, as they are able to 
provide a single estimate of the probability of a specific outcome. They can also be 
readily available in the clinical setting to aid in physician-patient interactions. Since 
nomograms are able to give individualized predictions, they can be used to identify and 
stratify patients for participation in clinical trials as well (Iasonos et al. 2008).  
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Appendix II: Variable List 
GUROC ProCaRS Database (N=7,974): Variable List  
# Variable Description 
1 ID Patient ID Number: Centre-XX (e.g. BCCA-1012) 
2 ID2 
Patient ID Number: 1, 2, 3,…,7973, 7974 [For Sorting 
Purposes Only] 
5 Centre Centre: 1, 2, 3, 4 
6 Centrex Centre: Description 
7 Cohort_7cat 
Cohort (7 categories): BCCA, PMH LDR, PMH Dose 
Escalation, PMH Trial #9907, Laval LDR, Laval HDR+EBRT, 
McGill 
8 Age Age 
9 BasePSA Baseline PSA (ng/mL) 
15 Tstage_CORR_4catx 
T-Stage (excluding Sub-Type): n = 7860 (frequency missing 
= 114) 
19 GleasonPattern_CORR Gleason Pattern: 1+1, 1+2…5+4, 5+5 
21 GleasonMajor_CORR 
Gleason Major: Re-derived based on FIRST number in 
Gleason Pattern   **CORRECTED** 
23 GleasonMinor_CORR 
Gleason Minor: Re-derived based on SECOND number in 
Gleason Pattern   **CORRECTED** 
25 GleasonTotal_CORR 
Total Gleason Score: Re-derived based on corrected 
Gleason Major and Minor  **CORRECTED** 
26 GleasonTotal_CORR_4cat 
Total Gleason Score (4 categories): (1) 2-5, (2) 6, (3) 7, (4) 
8-10 
34 PosCores_ge50pct Biopsy Cores: Postive Cores: (1) ≥ 50 % , (0) < 50% 
36 Bilat_Biopsy_Status_CORR Bilateral Biopsy Status: No, Yes, Unknown, N/A 
37 Hormones Hormones: (1) Yes, (0) No 
38 HormStart Hormones: Start Date 
39 HormEnd Hormones: End Date 
40 AdjHT_months 
Adjuvant Hormone Therapy (Months): ZEROs coded as 
MISSING 
41 AdjHT_monthsx 
Adjuvant Hormone Therapy (Months): ZEROs kept as 
ZEROs (for modelling) except if HormEnd Missing 
[Nomogram Manuscript] 
42 AdjHT_months_OLD 
Adjuvant Hormone Therapy (Months): ZEROs kept as 
ZEROs (for modelling) 
45 RTStart_Year_4cat 
RT Start Year (4 categories): (1) 1994-1999, (2) 2000-2002, 
(3) 2003-2005, (4) 2006-2010 
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GUROC ProCaRS Database (N=7,974): Variable List—Page 2/3 
# Variable Description 
48 EBRT EBRT: (1) Yes, (0) No 
49 EBRT_Dose EBRT Dose (cGy) 
50 EBRT_Dose_GT70 EBRT Dose: (1) > 70 Gy, (0) ≤ 70 Gy 
52 EBRT_Fractions EBRT: Number of Fractions 
53 EBRT_FractionDose EBRT: Dose per Fraction (cGy) 
54 EBRT_BED_Gy EBRT Biologic Equivalent Dose (Gy) 
55 LDR LDR: Low Dose Rate Brachytherapy 
56 LDR_Dose   
57 LDR_Fractions   
58 HDR HDR: High Dose Rate Brachytherapy 
59 HDR_Dose   
60 HDR_Fractions   
61 Brachy Brachytherapy: (1) Yes, (0) No 
62 Radiation_Type Radiation Type: Brachy + EBRT, Brachy only, EBRT only 
63 Radiation_Type_5cat 
Radiation Type (5 categories): Brachy(LDR) only, 
Brachy(HDR) only, EBRT only, Brachy(LDR) + EBRT, 
Brachy(HDR) + EBRT 
64 LocalRelapse Clin/Path confirmed Local Relapse 
66 PostRTHormStart Salvage Hormone Therapy Start Date 
67 Dead Dead: (1) Dead, (0) Alive 
68 Dead_5yr Dead (≤ 5 years): (1) Dead, (0) Alive 
71 Survival_months Survival in MONTHS 
78 CauseofDeath_CORRx Denominator = 7974 
87 Amico AMICO Classification: Low, Intermediate, High 
109 CRS 
Prostate Cancer Death (aka Cancer-Related/Specific 
Survival): (1) Yes, (0) No (Equivalent to "CRStatus") 
110 CRS_5yr Prostate Cancer Death (≤ 5 years): (1) Yes, (0) No 
112 CRS_months Cancer-Related/Specific Survival in MONTHS 
130 BFFS2 
Biochemical Failure (aka Biochemical-Failure-Free 
Survival): (1) Yes, (0) No (Equivalent to "PhBFFS2Stat" - 
ASTRO II Phoenix Definition) 
132 BFFS2_months Biochemical-Failure-Free Survival in MONTHS 
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GUROC ProCaRS Database (N=7,974): Variable List—Page 3/3 
# Variable Description 
134 BFFS2_CORR 
Biochemical Failure CORRECTED for PSA bounce 
(Brachytherapy patients with NO post-RT hormone therapy 
meeting previous ASTRO II Phoenix definition censored if 
LAST PSA ≤ 0.5 ng/mL). 
135 BFFS2_CORR_months Biochemical-Failure-Free Survival CORRECTED in MONTHS 
137 BFFS2_5yr Biochemical Failure CORRECTED (≤ 5 years): (1) Yes, (0) No 
138 BFFS2_months_5yr 
Biochemical-Failure-Free Survival CORRECTED in MONTHS 
(corresponds with "BFFS2_5yr") 
139 Nadir_PSA Nadir PSA (ng/mL) 
140 Nadir_Months Time-to-Nadir in MONTHS 
141 Post_BFFS2_CORR_months 
Time (months) from Biochemical Failure CORRECTED 
(BFFS2_CORR) to Death / Last Follow-up [Outcomes 
Manuscript / Tara's Post BF Analysis] 
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Appendix III: R Code and Output 
 
> # RPA Model 3.6: 5-Year Survival: All Factors (Survival Function):  
>  
> RPA36_5Yr_Both_Surv <- rpart (Surv (Post_BFFS2_CORR_Years, Dead_5Year) ~ Age + BasePSA 
+ factor(Tstage_CORR_4catx) + factor(GleasonTotal_CORR_4cat) + factor(Hormones) + 
factor(Radiation_Type_2cat) + factor(procars_5cat) + Nadir_PSA + Nadir_Months + 
BFFS2_CORR_months + PSA_DT_PreBF_NadirLast_NoNeg + PSA_DT_PreBF_Last2_NoNeg, maxdepth=3, 
na.action=na.omit, data=Training_N831) 
>  
> print(RPA36_5Yr_Both_Surv) 
n=349 (482 observations deleted due to missingness) 
 
node), split, n, deviance, yval 
      * denotes terminal node 
 
 1) root 349 440.16240 1.0000000   
   2) BFFS2_CORR_months< 77.14168 310 343.63300 0.8376554   
     4) PSA_DT_PreBF_Last2_NoNeg>=5.113436 236 226.07600 0.6230686   
       8) factor(GleasonTotal_CORR_4cat)=1_2to5,2_6,3_7 205 171.47460 0.4888697 * 
       9) factor(GleasonTotal_CORR_4cat)=4_8to10 31  40.70061 1.6572990 * 
     5) PSA_DT_PreBF_Last2_NoNeg< 5.113436 74  99.59061 1.6197440   
      10) Age< 65.5 24  25.67778 0.7836384 * 
      11) Age>=65.5 50  67.06904 2.0989240 * 
   3) BFFS2_CORR_months>=77.14168 39  72.95443 2.7292900   
     6) PSA_DT_PreBF_NadirLast_NoNeg>=11.82306 32  53.39676 2.0802530   
      12) factor(GleasonTotal_CORR_4cat)=1_2to5,2_6,4_8to10 24  26.84216 1.4566410 * 
      13) factor(GleasonTotal_CORR_4cat)=3_7 8  19.29453 4.2208080 * 
     7) PSA_DT_PreBF_NadirLast_NoNeg< 11.82306 7  10.72648 5.7438950 * 
> summary(RPA36_5Yr_Both_Surv) 
Call: 
rpart(formula = Surv(Post_BFFS2_CORR_Years, Dead_5Year) ~ Age +  
    BasePSA + factor(Tstage_CORR_4catx) + factor(GleasonTotal_CORR_4cat) +  
    factor(Hormones) + factor(Radiation_Type_2cat) + factor(procars_5cat) +  
    Nadir_PSA + Nadir_Months + BFFS2_CORR_months + PSA_DT_PreBF_NadirLast_NoNeg +  
    PSA_DT_PreBF_Last2_NoNeg, data = Training_N831, na.action = na.omit,  
    maxdepth = 3) 
  n=349 (482 observations deleted due to missingness) 
 
          CP nsplit rel error    xerror       xstd 
1 0.05355981      0 1.0000000 1.0057660 0.04972013 
2 0.04081761      1 0.9464402 1.0187924 0.05374824 
3 0.03158086      2 0.9056226 1.0072310 0.05512709 
4 0.02006348      3 0.8740417 0.9850322 0.05769114 
5 0.01649406      4 0.8539782 0.9954432 0.06072058 
6 0.01554835      5 0.8374842 1.0005402 0.06128865 
7 0.01000000      6 0.8219358 1.0046644 0.06187529 
 
Variable importance 
             BFFS2_CORR_months   PSA_DT_PreBF_NadirLast_NoNeg  
                            24                             19  
      PSA_DT_PreBF_Last2_NoNeg factor(GleasonTotal_CORR_4cat)  
                            18                             18  
                     Nadir_PSA                            Age  
                             7                              5  
     factor(Tstage_CORR_4catx)                   Nadir_Months  
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                             4                              3  
   factor(Radiation_Type_2cat)                        BasePSA  
                             1                              1  
 
Node number 1: 349 observations,    complexity param=0.05355981 
  events=109,  estimated rate=1 , mean deviance=1.26121  
  left son=2 (310 obs) right son=3 (39 obs) 
  Primary splits: 
      BFFS2_CORR_months              < 77.14168 to the left,  improve=23.70076, (0 
missing) 
      Nadir_PSA                      < 0.735    to the right, improve=16.24569, (0 
missing) 
      factor(GleasonTotal_CORR_4cat) splits as  LLLR,         improve=15.67358, (0 
missing) 
      PSA_DT_PreBF_Last2_NoNeg       < 5.113436 to the right, improve=14.05951, (0 
missing) 
      factor(Tstage_CORR_4catx)      splits as  LLRR,         improve=10.72834, (0 
missing) 
  Surrogate splits: 
      Nadir_Months             < 29.30595 to the left,  agree=0.897, adj=0.077, (0 split) 
      PSA_DT_PreBF_Last2_NoNeg < 85.52677 to the left,  agree=0.894, adj=0.051, (0 split) 
 
Node number 2: 310 observations,    complexity param=0.04081761 
  events=84,  estimated rate=0.8376554 , mean deviance=1.108493  
  left son=4 (236 obs) right son=5 (74 obs) 
  Primary splits: 
      PSA_DT_PreBF_Last2_NoNeg       < 5.113436 to the right, improve=17.98006, (0 
missing) 
      PSA_DT_PreBF_NadirLast_NoNeg   < 6.814712 to the right, improve=15.69468, (0 
missing) 
      factor(GleasonTotal_CORR_4cat) splits as  LLLR,         improve=14.96850, (0 
missing) 
      Nadir_PSA                      < 0.975    to the right, improve=12.69945, (0 
missing) 
      factor(procars_5cat)           splits as  LRLRR,        improve=11.67494, (0 
missing) 
  Surrogate splits: 
      PSA_DT_PreBF_NadirLast_NoNeg < 5.194712 to the right, agree=0.897, adj=0.568, (0 
split) 
      BFFS2_CORR_months            < 18.51335 to the right, agree=0.813, adj=0.216, (0 
split) 
      Nadir_PSA                    < 0.065    to the right, agree=0.790, adj=0.122, (0 
split) 
      factor(Radiation_Type_2cat)  splits as  LR,           agree=0.784, adj=0.095, (0 
split) 
      Nadir_Months                 < 2.036961 to the right, agree=0.777, adj=0.068, (0 
split) 
 
Node number 3: 39 observations,    complexity param=0.02006348 
  events=25,  estimated rate=2.72929 , mean deviance=1.870626  
  left son=6 (32 obs) right son=7 (7 obs) 
  Primary splits: 
      PSA_DT_PreBF_NadirLast_NoNeg   < 11.82306 to the right, improve=15.137290, (0 
missing) 
      factor(GleasonTotal_CORR_4cat) splits as  LLRR,         improve=12.785170, (0 
missing) 
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      Nadir_PSA                      < 0.235    to the right, improve=11.396040, (0 
missing) 
      PSA_DT_PreBF_Last2_NoNeg       < 10.69603 to the right, improve=11.259570, (0 
missing) 
      BasePSA                        < 9.8      to the left,  improve= 9.624019, (0 
missing) 
  Surrogate splits: 
      Nadir_PSA                 < 0.035    to the right, agree=0.897, adj=0.429, (0 
split) 
      factor(Tstage_CORR_4catx) splits as  RLLR,         agree=0.872, adj=0.286, (0 
split) 
      BFFS2_CORR_months         < 81.87269 to the right, agree=0.846, adj=0.143, (0 
split) 
      PSA_DT_PreBF_Last2_NoNeg  < 5.117525 to the right, agree=0.846, adj=0.143, (0 
split) 
 
Node number 4: 236 observations,    complexity param=0.03158086 
  events=49,  estimated rate=0.6230686 , mean deviance=0.957949  
  left son=8 (205 obs) right son=9 (31 obs) 
  Primary splits: 
      factor(GleasonTotal_CORR_4cat) splits as  LLLR,         improve=13.935100, (0 
missing) 
      Nadir_PSA                      < 1.305    to the right, improve=10.158680, (0 
missing) 
      factor(procars_5cat)           splits as  LRLRR,        improve= 8.836434, (0 
missing) 
      BFFS2_CORR_months              < 37.19097 to the left,  improve= 8.808492, (0 
missing) 
      factor(Tstage_CORR_4catx)      splits as  LLRR,         improve= 8.219032, (0 
missing) 
  Surrogate splits: 
      factor(Tstage_CORR_4catx) splits as  LLLR,         agree=0.873, adj=0.032, (0 
split) 
      Nadir_PSA                 < 7.65     to the left,  agree=0.873, adj=0.032, (0 
split) 
 
Node number 5: 74 observations,    complexity param=0.01554835 
  events=35,  estimated rate=1.619744 , mean deviance=1.345819  
  left son=10 (24 obs) right son=11 (50 obs) 
  Primary splits: 
      Age                         < 65.5     to the left,  improve=6.883038, (0 missing) 
      factor(Radiation_Type_2cat) splits as  RL,           improve=6.180697, (0 missing) 
      BasePSA                     < 20.95    to the right, improve=4.838822, (0 missing) 
      Nadir_Months                < 1.445585 to the left,  improve=3.954354, (0 missing) 
      factor(Tstage_CORR_4catx)   splits as  LRRR,         improve=3.922247, (0 missing) 
  Surrogate splits: 
      BasePSA                      < 4.05     to the left,  agree=0.730, adj=0.167, (0 
split) 
      Nadir_Months                 < 1.445585 to the left,  agree=0.689, adj=0.042, (0 
split) 
      PSA_DT_PreBF_NadirLast_NoNeg < 14.78638 to the right, agree=0.689, adj=0.042, (0 
split) 
 
Node number 6: 32 observations,    complexity param=0.01649406 
  events=18,  estimated rate=2.080253 , mean deviance=1.668649  
  left son=12 (24 obs) right son=13 (8 obs) 
  Primary splits: 
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      factor(GleasonTotal_CORR_4cat) splits as  LLRL,         improve=9.400000, (0 
missing) 
      Age                            < 67       to the left,  improve=5.823388, (0 
missing) 
      BasePSA                        < 11.4     to the left,  improve=4.409422, (0 
missing) 
      BFFS2_CORR_months              < 96.9692  to the left,  improve=2.909912, (0 
missing) 
      factor(Hormones)               splits as  LR,           improve=2.608843, (0 
missing) 
  Surrogate splits: 
      BFFS2_CORR_months        < 82.9076  to the right, agree=0.812, adj=0.250, (0 split) 
      PSA_DT_PreBF_Last2_NoNeg < 7.477049 to the right, agree=0.812, adj=0.250, (0 split) 
      Nadir_Months             < 5.190965 to the right, agree=0.781, adj=0.125, (0 split) 
 
Node number 7: 7 observations 
  events=7,  estimated rate=5.743895 , mean deviance=1.532354  
 
Node number 8: 205 observations 
  events=34,  estimated rate=0.4888697 , mean deviance=0.8364617  
 
Node number 9: 31 observations 
  events=15,  estimated rate=1.657299 , mean deviance=1.312923  
 
Node number 10: 24 observations 
  events=6,  estimated rate=0.7836384 , mean deviance=1.069907  
 
Node number 11: 50 observations 
  events=29,  estimated rate=2.098924 , mean deviance=1.341381  
 
Node number 12: 24 observations 
  events=11,  estimated rate=1.456641 , mean deviance=1.118423  
 
Node number 13: 8 observations 
  events=7,  estimated rate=4.220808 , mean deviance=2.411816  
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